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Summary 
Endocannabinoids (eCB) are signaling lipids and became known for their importance in the 
central nervous system as well as in immune defense. Beneficial effects of eCB are shown in 
processes of excitotoxic lesion, secondary damage and neuronal plasticity throughout the last 
years. Two canabinoid receptors, type 1 (CB1) and type 2 (CB2) as the respective endogenous 
ligands belong to the endocannabinoid system (eCBS). In 1990, the CB1 could be cloned and 
was localised mainly on neurons. Shortly thereafter in 1993, the CB2 was characterised and 
found  primarily  on  cells  belonging  to  the  immune  system.  N-arachidonoylethanolamide 
(AEA),  often  called  anandamide,  and  2-arachidonoylglycerol  (2-AG)  are  the  best 
characterised eCB. N-palmitylethanolamide (PEA) and N-oleoylethanolamide (OEA) have no 
or only low affinity to  CB1 but enhance the affinity of AEA significantly. This  group is 
therefore often summarized as N-ethanolamides (NEA). ECB are derivates of arachidonic 
acid and are stored in membranes where they become hydrolysed on demand by specific 
enzymes. Traumatic brain injury altered the levels of eCB in the blood in vivo and when 
applied  in  vitro  after  neuronal  damage,  eCB  could  reduce  the  damaging  burden.  Further 
studies demonstrated that eCB are potent to down-regulate pro-inflammatory cytokines and 
most important to decrease neuronal excitation. 
In the present study, the intrinsic regulation of the endocannabinoid system after neuronal 
damage over time was investigated in rat Organotypic Hippocampal Slice Cultures (OHSC). 
Temporal and spatial dynamics of eCB levels were analysed after transection of the perforant 
pathway  (PPT)  in  originating  neurons  (enthorhinal  cortex,  EC),  areas  of 
deafferentiation/anterograde axonal degeneration (dentate gyrus, DG) and of the synaptically 
linked cornu ammonis region 1 (CA1) as well as after excitotoxic lesion in the respective 
regions. 
A strong increase of all eCB was observed only in the denervation zone of the DG 24 hours 
post PPT. In excitotoxic lesioned OHSC all eCB were elevated, in the investigated regions up 
to 72 hours post lesion (hpl). The responsible enzyme for biosynthesis of the NEA, NAPE-
PLD  protein,  was  increased  during  the  early  timepoints  of  measurement  (1-6  hpl).  The 
responsible catabolizing enzyme, FAAH, and the CB1 receptor were up-regulated at a later 
timepoint,  48  hpl,  explaining  the  eCB  levels.  In  the  present  model,  the  inhibition  of  the 
enzyme responsible for 2-AG hydrolysis (MAGL) was neuroprotective as previously shown IV 
 
and  a  re-distribution  within  neurons  and  astrocytes  during  neuronal  damage  could  be 
observed. In primary cell cultures microglia expressed the regulating enzymes of 2-AG and 
the enzyme responsible for NEA down-regulation, FAAH. Astrocytes expressed mainly the 
catalyzing  enzymes,  indicating  the  role  for  eCB  break-down.  All  these  findings  together 
demonstrate  the  great  capacity  of  the  eCBS  to  control  inflammatory  processes  and 
consequently neuronal cell death.  
All effects of the known eCB could not be clarified by CB1/CB2 deficient mice. Several 
G-protein coupled receptors (GPR) are recently in discussion whether they might and should 
belong to the endocannabinoid system. The GPR55, the not yet cloned abnormal cannabidiol 
receptor and further GPRs are candidates as potential endocannabinoid receptors. Recently 
GPR55 has been discussed as a putative cannabinoid receptor type 3 (CB3). Quantitative PCR 
revealed that Gpr55 is present in primary microglia and the brain, but the exact regional and 
cellular  distribution  and  the  physiological/pathological  effects  downstream  of  GPR55 
activation  in  the  CNS  still  remain  open.  Therefore,  the  excitotoxic  rat  OHSC  model, 
previously  used  to  investigate  the  neuroprotective  potency  of  eCB,  was  now  used  to 
investigate the neuroprotective potency of GPR55. Activation of GPR55 protected dentate 
gyrus granule cells in vitro after excitotoxic lesion, induced by NMDA. In parallel, GPR55 
activation  was  able  to  reduce  the  number  of  microglia  in  the  dentate  gyrus.  These 
neuroprotective effects vanished however in microglia depleted OHSCs as well as in OHSC 
transfected  with  Gpr55  siRNA,  indicating  a  strong  involvement  of  microglia  in  GPR55 
mediated neuroprotection.  
In summary, the present study found a strong time-dependent and anterograde mechanism of 
action  of  eCB  after  long-range  projection  damage  and  provided  further  evidence  for  the 
neuroprotective properties of eCB. The potential cannabinoid receptor 3 (GPR55) mediates 
neuronal protection on behalf of microglia. 
   V 
 
 
Zusammenfassung 
Endocannabinoide  (eCB)  sind  lipophile  Signalstoffe  und  für  Ihre  Wirkung  im  zentralen 
Nervensystem und Immunsystem bekannt. Dem intrinsischem Cannabinoid System werden 
die  Cannabinoid  Rezeptoren  des  Typs  1  (CB1)  und  2  (CB2),  sowie  die  dazugehörigen 
endogenen Liganden zugeordnet. Der CB1 Rezeptor wurde 1990 kloniert und hauptsächlich 
auf Neuronen lokalisiert. Dieser Rezeptor ist nachweisbar für die psychotrope Wirkung des 
Phytocannabinoid THC verantwortlich. Ein weiterer G-Protein gekoppelter Rezeptor, CB2, 
welcher auf Immunzellen vorkommt, wurde 1993 aufgeklärt. Jedoch könnten in Kürze noch 
nicht klonierte Rezeptoren dem eCB System (eCBS) zugeordnet werden, da diese potentiellen 
Rezeptoren  durch  eCB  aktivierbar  sind.  CB1  und  CB2  defiziente  Mäuse  konnten  in 
pharmakologischen Studien die Wirkung der unterschiedlichen eCB nicht vollständig klären. 
Der G-Protein gekoppelte Rezeptor GPR55, als auch der sogenannte, noch nicht klonierte, 
abnormale Cannabidiol Rezeptor sind Kandidaten für das eCBS.  
N-Arachidonylethanolamin  (AEA)  und  2-Arachidonylglycerin  (2-AG)  sind  Derivate  der 
Arachidonsäure  und  die  am  Besten  untersuchten  Substanzen  der  eCB.  AEA  wird  oft  mit 
N-Palmitylethanolamin  (PEA)  und  N-Oleoylethanolamin  (OEA)  zur  Gruppe  der 
N-Ethanolamine (NEA) zusammengefasst. Die Wirkung der eCB ist an den CB Rezeptoren 
unterschiedlich, so ist 2-AG ein Vollagonist an beiden CB Rezeptoren, AEA ein Vollagonist 
am  CB1  Rezeptor  und  ein  Partialagonist  am  CB2  Rezeptor.  PEA  und  OEA  stellen  eine 
Besonderheit dar, da beide nicht an den CB Rezeptoren binden, jedoch die Bindung von AEA 
am CB1 Rezeptor erhöhen.  
Die  Wirkung  der  eCB  wird  enzymatisch  reguliert,  da  eCB  mit  ihrem  stark  lipophilen 
Charakter  nicht  in  sekretorischen  Vesikeln  sondern  aktivitätsabhängig  aus  Lipiden  der 
Zellmembran synthetisiert werden. Die Gruppe  der NEA  wird aus  dem Vorläufermolekül 
N-arachidonylphosphatidylethanolamin  vom  Enzym  N-acylphosphatidylethanolamin 
Phospholipase D (NAPE-PLD) synthetisiert. Der Abbau von NEA wird von zwei Enzymen 
(Fettsäureaminhydrolase  (FAAH)  und  N-Acylethanolamidsäure  Amidase  (NAAA)) 
intrazellulär übernommen. Der genaue Transportmechanismus von eCB ist noch unbekannt, 
neben der passiven Diffusion werden Membrantransporter diskutiert.  
Die  Synthese  von  2-AG  wird  mit  der  Phospholipase  C  und  Inositol  Phospholipiden  oder 
Phosphatidylcholin  initiiert  und  durch  Diacylglycerinlipase  (DAGL)  vervollständigt. VI 
 
Monoacylglycerinlipase  (MAGL)  ist  das  2-AG  deaktivierende  Enzym,  welches  2-AG  zu 
Arachidonsäure und Glycerin abbaut.  
 
Nach traumatischen Schädigungen steigen eCB Mengen im Gewebe sowie im Blut deutlich 
an. Es konnte weiter auch eine Neuroprotektion von exogen applizierten eCB nach neuronaler 
Schädigung in vitro gezeigt werden. Die Reduktion der neuronalen Schädigung erfolgt durch 
die Einschränkung der Erregbarkeit von Neuronen, da die glutamaterge Transmission durch 
verminderten Kalziumeinstrom eingeschränkt wird. Es erfolgt jedoch auch eine verminderte 
Freisetzung von proinflammatorischen Zytokinen, wie z.B. TNF-alpha.  
In der vorliegenden Arbeit wurden zwei Fragestellungen bearbeitet. Die erste Fragestellung 
sollte  die  Regulation  von  eCB  nach  unterschiedlicher  neuronaler  Schädigung  am 
Modellsystem der organotypischen hippokampalen Schnittkultur (OHSC) untersuchen: zum 
Einen nach exzitotoxischer Läsion durch Applikation von N-Methyl-D-Aspartat (NMDA) und 
zum Anderen in retrograd und anterograd geschädigten Arealen nach axonaler Transektion. 
Die  weitere  Fragestellung  der  vorliegenden  Arbeit,  war  der  Einfluss  des  potentiellen  CB 
Rezeptors GPR55 auf neuronale exzitotoxische Schädigung im Modell der OHSC. 
Für beide Fragestellungen wurden OHSC von 8 Tage alten Ratten präpariert und kultiviert. 
Für die exzitotoxische Läsion wurden OHSC mit Hilfe von 50 µM NMDA geschädigt und 
nach unterschiedlichen Zeitpunkten fixiert. Die exzitotoxische Läsion bewirkt eine massive 
neuronale Erregung und somit neuronales Sterben sowie eine Aktivierung der Gliazellen in 
der  gesamten  hippocampalen  Region.  Die  axonale  Transektion  der  perforanten  Projektion 
verursacht  eine  lokal  begrenzte  Schädigung,  welche  im  Entorhinalen  Cortex  (EC)  eine 
retrograde Schädigung und im Gyrus Dentatus (DG) sowie in der Cornu Ammonis Region 1 
(CA1) eine anterograde Schädigung  zur Folge hat. 
Die  beschriebenen  Regionen  wurden  nach  exzitotoxischer  Läsion  und  nach  axonaler 
Transektion auf ihre eCB Menge nach 0, 1, 6, 12, 24, 48 und 72 Stunden sowie 72 Stunden 
nach Applikation  des  MAGL  Inhibitors JZL184  mit  Hilfe von Flüssigchromatografie und 
Massenspektrometrie  untersucht.  Die  regulierenden  Enzyme  und  die  Rezeptoren  CB1  und 
PPARalpha  konnten  mittels  Immunhistochemischen  Methoden  und    semiquantitativer 
Echtzeit polimerase-Kettenreaktion (rtPCR) dargestellt werden. OHSC wurden mittels Magl 
siRNA  und  dem  MAGL  Inhibitor  JZL184  wie  im  Folgenden  beschrieben  auf  ihre 
Neuroprotektivität  untersucht.  Zur  Bestimmung  der  neuronalen  Schädigung  nach  MAGL 
Reduktion  und  GPR55  Aktivierung  wurde  die  Anzahl  der  toten  Körnerzellen  und  der VII 
 
Mikroglia  des  DG  quantifiziert  und  mit  der  unbehandelten  NMDA  Kontrolle  verglichen.  
Propidiumiodid  (PI)  diente  als  Marker  für  degenerierte  Neurone  und  FITC-konjugiertes 
Griffonia simplicifolia Isolektin B4 (IB4) wurde als Mikrogliamarker verwendet. Dargestellt 
und analysiert wurden die OHSC mit einem konfokalen Laserscanning Mikroskop.  
Zur  Überprüfung  der  GPR55  vermittelten  Neuroprotektion  wurden  Versuche  mit  Gpr55 
siRNA transfizierten OHSC und Mikroglia depletierten OHSC durchgeführt. Versuche mit 
verschiedenen  synthetischen  Agonisten/Antagonisten  (WIN,  AM281)  des  CB1  Rezeptors 
wurden  durchgeführt  um  mögliche  Interaktionen  zu  identifizieren.  Die  Wirkung  des 
verwendeten GPR55 Liganden L-alpha Lysophosphatidylinositol (LPI) wurde weiterführend 
mit Hilfe von Migrationsversuchen mit Mikroglia untersucht.  
Das  Modell  der  OHSC  konnte  erfolgreich  zur  Bestimmung  der  eCB  Regulation  nach 
neuronaler  Schädigung  genutzt  werden,  da  die  eCB  Mengen  der  beschriebenen  Areale 
bestimmt  und  auf  ihren  Aktingehalt  normiert  werden  konnten.  Nach  exzitotoxischer 
Schädigung konnte im EC ein Anstieg von NEA nach 24 Stunden beobachtet werden. Im DG 
waren NEA über den gesamten gemessenen Zeitraum erhöht, 2-AG war nach 24 Stunden und 
72 Stunden signifikant erhöht.  In der CA1 Region waren alle eCB 24 und 72 Stunden nach 
Läsion  hochreguliert.  Im  Schädigungsmodell  der  axonalen  Transektion  wurde  allein  im 
anterograd  gelegenen  DG  eine  Erhöhung  der  eCB  nach  24  Stunden  festgestellt.  Die 
enzymatische Regulation von NEA zeigte einen Anstieg des synthetisierenden Enzym NAPE-
PLD nach einer und sechs Stunden post Läsion. Das abbauende Enzym FAAH war nach 
48 Stunden hochreguliert. Das 2-AG synthetisierende Enzym DAGL war 24 Stunden post 
Läsion im DG in Western Blot Analysen herunter reguliert, zeigte jedoch in rtPCR Analysen 
eine Hochregulation 24 Stunden post Läsion. Das 2-AG katalysierende Enzym MAGL war 
keinen Veränderungen in Western Blot und rtPCR Analysen unterworfen. Der CB1 Rezeptor 
zeigte eine marginale Erhöhung 6 Stunden nach axonaler Schädigung im EC und 48 Stunden 
nach Läsion in der CA1 Region. Die Auswertung der immunhistochemischen Färbungen im 
DG ergab für NAPE-PLD eine neuronale und Mikroglia positive Lokalisierung. FAAH und 
NAAA  konnten  auch  neuronal  exprimiert  dargestellt  werden.  In  primären  Zellkulturen 
wurden unterschiedliche Exprimierungsmuster zu den OHSC sichtbar. Hier wurden NAPE-
PLD, FAAH und NAAA schwach in Gliazellen exprimiert als auch neuronal. In OHSC war 
DAGL neuronal lokalisiert. Nach neuronaler Schädigung, axonal oder exzitotoxisch, zeigten 
auch Astrozyten DAGL Expressionen. Das 2-AG katalysierende Enzym MAGL konnte unter 
Kontrollbedingungen  zunächst  in  Neuronen  und  Astrozyten  mit  Hilfe  von 
immunhistochemischen Färbungen sichtbar gemacht werden, jedoch nicht nach neuronaler VIII 
 
Schädigung im DG. Anders stellte sich die Expression in  primären Zellkulturen dar, hier 
zeigten sich Mikroglia und Astrozyten DAGL positiv. MAGL wurde in Mikroglia exprimiert 
und stellte sich nur nach Schädigung der Zellkulturen mit LPS auch in Astrozyten dar. Die 
beiden Rezeptoren CB1 und PPARα waren in Neuronen exprimiert, PPARα konnte auch in 
Mikroglia gezeigt werden.  
Die  neuroprotektive  Eigenschaft  von  endogenem  2-AG  konnte  mit  Hilfe  des  MAGL 
Inhibitors  JZL184  dargestellt  werden.  Nach  Gabe  von  JZL184  war  in  allen  untersuchten 
Arealen  der  OHSC  eine  erhöhte  Menge  an  2-AG  zu  messen.  Im  Vergleich  zu  NMDA 
geschädigten OHSC welche keine JZL184 oder MAGL siRNA Behandlung bekamen, war die 
Anzahl  der  PI  positiven  Neurone  in  der  Körnerzellschicht  des  DG  signifikant  gesunken. 
Unbeschädigte OHSC  wiesen kaum  PI  positive Neurone und nur wenige  ramifizierte  IB4 
positive Mikrogliazellen auf.  
Nach Applikation des GPR55 Liganden LPI für 72 Stunden, konnte keine Veränderung in 
OHSC festgestellt werden. OHSC wurden mit NMDA für 4 Stunden geschädigt und wiesen 
72  Stunden  darauf  ein  hohes  Maß  an  PI  positiven  Neuronen  und  vielen  amöboiden  IB4 
positiven  Mikrogliazellen  auf.  Die  Anzahl  der  PI  positiven  Neuronen  und  IB4  positiven 
Mikroglia  reduzierte  sich  signifikant  bei  NMDA  Schädigung  und  Applikation  von  LPI 
(0.1-10 µM). Präapplikation von LPI (1 µM) vor der Schädigung mit NMDA und zeitliche 
Veränderungen von LPI Applikation, führten zu keiner Reduktion der PI positiven Neurone 
oder  IB4  positiven Mikrogliazellen. Der CB1  Agonist WIN55 212-2 und CB1  Antagonist 
AM281 konnten die Wirkung von  LPI  auf  IB4  positive Mikroglia aufheben, jedoch hatte 
AM281 keinen Einfluss auf die Reduktion der PI positiven Neurone. Die GPR55 vermittelte 
Neuroprotektion konnte mit GPR55 siRNA transfizierten OHSC und Mikroglia depletierten 
OHSC aufgehoben werden. Desweiteren konnte eine chemoattraktive Wirkung von LPI auf 
Mikroglia festgestellt werden.  
Die  erste  Fragestellung  beschäftigte  sich  mit  der  Regulation  der  eCB.  Diese  sind  nach 
neuronaler  Schädigung  zeitlich  und  anterograd  gerichtet  reguliert  und  weisen  auf  ein 
endogenes neuroprotektives System. Dies könnte weiterführend auch auf einen Einfluss der 
eCB auf dendritische Reorganisation nach Wegfall des empfangenden Signals deuten. Die 
bisher  bekannten  Enzyme  konnten  die  Regulation  von  NEA  erklären,  jedoch  scheint  das 
katalysierende Enzym NAAA nach neuronaler Schädigung nicht involviert zu sein. Für das 
2-AG  synthetisierende  Enzym  DAGL  ist  ein  Abfall  des  Proteins  mit  einer  gleichzeitigen 
Erhöhung des Transkripts beobachtet worden. Die Wirkung von eCB ist zeitlich und räumlich IX 
 
begrenzt, daher könnte diese Resultate auf eine Ubiquitin gesteuerte Regulation hinweisen. 
Die Expression von DAGL nach neuronaler Schädigung in  Astrozyten bezeugt eine hohe 
Flexibilität der eCB Regulation und das Zusammenspiel unterschiedlicher Zellpopulationen 
im  ZNS.  Die  eindeutig  neuroprotektive  Wirkung  von  eCB  nach  neuronaler  Schädigung, 
verbunden mit der hier gezeigten Regulation, ermöglicht nun die spezifische Manipulation 
des  eCBS  um  potentielle  Therapien  im  Bereich  der  traumatischen  Schädigung  und 
Wirbelsäulenverletzungen zu testen.  
Die zweite Fragestellung mit  Bezug auf die Rolle des GPR55 Rezeptors nach neuronaler 
Schädigung konnte mit Hilfe des GPR55 Liganden LPI studiert werden. Die Applikation von 
LPI bewirkte eine Neuroprotektion und führte zu einer verminderten Mikroglia Anzahl in 
OHSC nach exzitotoxischer Schädigung. Dieser neuroprotektive Effekt von LPI wurde durch 
ein  Ausschalten  von  GPR55  oder  nach  Entfernung  der  immunkompetenten  Mikroglia 
aufgehoben.  Dies  hebt  die  prominente  Rolle  der  Mikrogliazellen  in  der  Protektion  von 
Neuronen durch GPR55 hervor. Auch die hier gezeigte chemoattraktive Wirkung von LPI auf 
Mikrogliazellen weist auf eine wichtige Signalfunktion von LPI selbst.   
Zusammenfassend untermauert die vorliegende Arbeit teilweise bekannte Befunde und zeigt 
interessante neue Erkenntnisse der neuroprotektiven Wirkung des eCBS. Die Daten bieten 
eine Ausgangsbasis für spezifische Modulationen des eCBS mit exogenen Cannabinoiden für 
mögliche Therapien bei traumatischen neuronalen Schädigungen.  
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1.  General Introduction   
 
Stroke,  spinal  cord  injury  (SCI)  and  traumatic  brain  injury  (TBI)  are  common  health 
threatening incidences in our society. Severe physical and mental impairments of the patient 
and high costs for our health system are often the result of central nervous tissue damage 
(Blight 1985; Signoretti, Vagnozzi et al. 2010). The endocannaboid system (eCBS) is induced 
in various brain disorders and is involved in both, neuronal protection as well as secondary 
damage. The result however, is dependent on cannabinoid derivate and receptor subtype. To 
understand the eCBS in the healthy organism and during pathologic variances, as well as to 
manipulate the eCBS pharmacologically, it is important to obtain knowledge of its intrinsic 
regulation.   
In  the  present  chapter  the  endocannabinoid  system  in  the  field  of  neurobiology  will  be 
presented, explaining the aim and relevance of the present dissertation. The second chapter 
describes the used material and methods followed by the third chapter describing the results 
of the present dissertation. Finally, the results will be discussed in chapter four. 
 
1.1  The endocannabinoid system 
Background and discovery 
Cannabis sativa (cannabis) was one of the first plants cultivated and used by mankind. The 
world  oldest  pharmacopoeia,  the  chinese  pen-ts’ao  ching  containing  medical  knowledge 
reaching back until 2700 years BC, reported for the first time medicinal cannabis indication 
(Read, 1936). At that time, cannabis was used for rheumatic pain, intestinal constipation, 2 
 
female disorders and further diseases. The cannabis plant was also regarded as a holy plant in 
asian shamanism, hinduism and buddhism, not only due to its beneficial health effects, but 
also to facilitate meditation (Köfalvi, Attila, 2012)[e-book]. 
In 1839 the first publication on cannabis in the western world was written by Wiliam B. 
O’Saughnessy, an irish physician ‘On the preparations of the Indian hemp, or gunjah’ starting 
with:‘… the narcotic effects of Hemp are popularly known in the south of Africa, South 
America, Turkey, Egypt, Middle East, Asia, India and the adjacent territories of the Malays, 
Burmese and Siamese … ’, further:’… extensively employed for a multitude of affections … ’ 
(Frankhauser  2002).  The  broad  affections  of  the  Indian  hemp  were  hardly  known  in  the 
European area at this time. After the publication of O’Saughnessy many investigations started 
with the hope to find new remedies. After several years however, the Indian hemp was almost 
forgotten and even  got  forbidden by law due to its  mental  effects.  New pharmacological 
possibilities and therapeutics were available and the plant cannabis lost its importance in the 
popular medical use.  
The interest in the possible medical force of cannabis sativa still continued. In 1990 the first 
endogenous cannabis receptor was identified on behalf of the main psychoactive ingredient of 
cannabis, Δ
9-tetrahydrocannabinol (Δ
9-THC). The molecular characterisation of the neuronal 
cannabinoid  receptor  type  1  (CB1)  released  a  new  and  enormous  interest  in  the  field  of 
cannabis, publications were 3-times enhanced compared to the years before (Köfalvi, 2008). 
After CB1 the characterisation of the cannabinoid receptor type 2 (CB2) followed and their 
endogenous  ligand  `anandamide`  was  detected,  now  more  than  20  years  ago.  A  new 
endogenous signaling system was discovered. The endocannabinoid system is involved  in 
important cognitive, sensory, motor and metabolic functions of our organism. Accordingly, 
the pharmacological research focuses on unraveling the various endogenous ligands and its 
receptors.  3 
 
For  about  80  years  now,  the  use  of  cannabis  is  forbidden  and  regarded  as  illicit  drug. 
However, cannabis is regaining its character as a medicinal plant. At the moment it is used 
legally in just a few countries but research with its developing possibilities will unravel its 
properties, which might be applied in favor of our physical and mental health.  
 
1.2  Cannabinoid receptors  
The CB1 receptor found in 1990 by Matsuda et al. showed that psychotropic cannabinoids can 
inhibit adenylate cyclase by acting through the G-i/o proteins (Munro, Thomas et al. 1993). It 
was  also  Munro et  al,  who shortly thereafter discovered the second cannabinoid receptor 
(CB2) (Munro, Thomas et al. 1993). The similarity of the CB1 and CB2 was leading to the 
conclusion that cannabinoids act on the superfamily of G-protein coupled receptors (GPR). 
CB1  consists  of  seven  alpha  helical  transmembrane  domains  with  a  68%  amino  acid 
homology within the transmembrane domains and with a 44% overall homology to CB2 (Lutz 
2002).  Three  more  GPRs,  GPR55,  GPR18  and  GPR119  are  intensively  discussed  as 
cannabinoid receptors due to the activating ability of endocannabinoids at these receptors. 
Other  receptors  are  also  in  discussion,  e.g.  the  abn-CBD  receptor  or  the  TRPV  channels 
(Begg, Pacher et al. 2005; Brown 2007; Pertwee, Howlett et al. 2010; McHugh, Page et al. 
2012)  
CB1 is the most abundant GPR in the brain, found mainly at the central and peripheral nerve 
terminals where it inhibits transmitter release (Pertwee 1997; Howlett 1998). The highest CB1 
concentration was found on perisynaptic axons of GABA and glutamatergic neurons in the 
hippocampus, basal ganglia, the cerebellum and the cortex (Herkenham, Lynn et al. 1991; 
Katona, Sperlagh et al. 1999; Morozov and Freund 2003; Katona, Urban et al. 2006). The 
expression pattern of CB1 on astrocytes and microglia is discussed controversially in literature 
but there is evidence showing CB1 on rat microglia (Bouaboula, Poinot-Chazel et al. 1995; 4 
 
Salio, Doly et al. 2002; Facchinetti, Del Giudice et al. 2003; Walter, Franklin et al. 2003; 
Stella 2004; Ramirez, Blazquez et al. 2005) and also on astrocytes (Navarrete and Araque 
2008). To a lesser extent CB1 is present in adipose tissue, liver, muscle, adrenal gland and the 
gastro intestinal tract (Pagotto, Marsicano et al. 2006).  
CB2 is predominantly (10-100 -fold higher than CB1) expressed in the immune system and 
modulates  cytokine  production  and  immune  cell  migration  (Munro,  Thomas  et  al.  1993; 
Galiegue, Mary et al. 1995; Kurihara, Tohyama et al. 2006). Expression of CB2 has been 
confirmed in many immune cells like neutrophils, macrophages, T cells and B cells, as well as 
in the endothelium of blood vessels and different tissues like spleen and thymus (Galiegue, 
Mary et al. 1995; Pertwee 1997; Kishimoto, Gokoh et al. 2003; Maestroni 2004; Howlett 
2005). Osteoblast and osteoclast are also CB2 positive (Bab and Zimmer 2008). In the central 
nervous  system  CB2  is  found  on  microglia  and  to  a  minor  extent  in  neurons  but  not  on 
astrocytes (Carlisle, Marciano-Cabral et al. 2002; Walter, Franklin et al. 2003; Carrier, Kearn 
et al. 2004; Nunez, Benito et al. 2004; Maresz, Pryce et al. 2007; Brusco, Tagliaferro et al. 
2008; Dittel 2008). On neurons, CB2 is found in regions including the cerebellum (Ashton, 
Friberg et al. 2006), brainstem (Van Sickle, Duncan et al. 2005), thalamus, striatum, cortex, 
amygdala  and  hippocampus  (Gong,  Onaivi  et  al.  2006),  as  well  as  in  the  spinal  cord 
(Beltramo,  Bernardini  et  al.  2006).  However,  protein  content  measured  by  Western  blot 
analysis or PCR makes it difficult to conclusively determine the cell type expressing CB2 
receptors (Van Sickle, Duncan et al. 2005; Ashton, Friberg et al. 2006; Beltramo, Bernardini 
et al. 2006; Cabral, Raborn et al. 2008). 
Several not yet cloned receptors might belong to the eCBS and still need to be characterised 
e.g. the orphan G protein coupled receptor GPR55 (Matsuda, Lolait et al. 1990; Mackie 2006; 
Mackie and Stella 2006; Petitet, Donlan et al. 2006; Harkany, Guzman et al. 2007; Pertwee 
2010; Pertwee, Howlett et al. 2010). GPR55 is recently discussed whether it should become 5 
 
the cannabinoid receptor type 3 (CB3).  Pharmacological enterprises claimed GPR55 in 2004, 
((Ryberg,  Larsson  et  al.  2007),  Class  A  Orphans:  GPR55.  Last  modified  on  30/11/2011,  
accessed on 06/07/2012  IUPHAR database) however, Oka et al. refuted the claim having 
evidence  that  the  endogenous  L-alpha-lysophosphatidyl  inositol  (LPI)  is  a  GPR55  ligand 
(Oka,  Nakajima  et  al.  2007).  LPI  does  not  belong  to  the  eCB  but  to  the  group  of 
lysophospholipids hydrolysed by the phospholipase A (PLA) from phosphatidylinositol and is 
localised  in  plasma  membranes.  It  was  first  shown  by  Falasca  et  al.  that  LPI  possesses 
mitogenic  abilities  (Falasca  and  Corda  1994).  However,  LPI  has  no  direct  cannabinoid 
receptor affinities and offers therefore the possibility to investigate the patho-physiological 
role of GPR55 without simultaneous CB1 or CB2 activation. The expression pattern of GPR55 
is contradictory. Johns et al. stated that GPR55 is mainly expressed in adipose tissue and in 
brain (Johns, Behm et al. 2007), whereas Ryberg et al. did not find GPR55 in adipose tissues 
(Ryberg, Larsson et al. 2007). GPR55 expression was also found in adrenal glands, parts of 
the gastrointestinal tract, the CNS and on endothelial cells (Lauckner, Jensen et al. 2008; 
Waldeck-Weiermair, Zoratti et al. 2008; Obara, Ueno et al. 2011; Romero-Zerbo, Rafacho et 
al.  2011).  First  GPR55  was  thought  to  be  the  missing  abnormal  cannabidiol  (abn-CBD) 
receptor due to the presence of GPR55 on blood vessels (Jarai, Wagner et al. 1999). This 
hypothesis was rejected by Johns et al. (2007), showing that GPR55 KO mice had no changed 
basal blood pressure and heart rate compared with wild-type mice. Abn-CBD also did not 
mediate the vascular changes via GPR55 in the mesenteric artery (Johns, Behm et al. 2007).  
 
1.3  Cannabinoid receptor ligands  
Cannabinoids  are  differentiated  into  three  groups:  First  the  bioactive  substances  of  the 
cannabis plant, second the endocannabinoids and finally the synthetic cannabinoids. Although 
the present study investigates the intrinsic temporal dynamics of the eCBS the most known 6 
 
plant derived cannabinoid and the best characterised aminoalkylindole is described shortly to 
clarify the differences to the group of endocannabinoids.     
 
Plant-derived cannabinoids 
The best known phytocannabinoid is Δ
9
-THC but there exist about 65 more plant-derived 
active cannabinoids (Di Marzo et al. 2004). Δ
9
-THC binds to both cannabinoid receptors with 
low affinity  and is  a partial agonist  (Pertwee 1997; Howlett  2002). Further plant-derived 
cannabinoids are tricyclic dibenzopyran derivatives (Klein 2005). 
 
Aminoalkylindoles 
WIN55212-2  is  a  synthetic  CB1  agonist,  coincidently  found  by  the  company  Sterling-
Winthrop.  The  chemical  structure  is  different  from  the  structure  of  natural  cannabinoids, 
belonging to the pravidoline derivates. However, in vivo WIN55212-2 is a very potent CB1 
agonist showing high similarity to Δ
9-THC effects (Jarbe, Li et al. 2010).  
 
Endocannabinoids 
After the cannabinoid receptors were identified, two endogenous ligands were discovered, 
belonging to the group of eicosanoids. The endocannabinoids (eCB) have a polyunsaturated 
fatty  acid  chain  with  a C20 body and a polar  head chain  linked with  an ester- or ether- 
binding. The present knowledge states that eCB act in the CNS as neurotransmitter integrated 
in the cell membrane and become released on demand (Pertwee 2008). Well characterised 
eCB like N-arachidonoylethanolamine (anandamide) or 2-arachidonoylglycerol (2-AG) are 
partial  or  full  agonists  at  CB1  and  CB2,  described  later  on  (Devane,  Hanus  et  al.  1992; 
Sugiura,  Kondo  et  al.  1995).  However,  some  structurally-related  fatty  acids  like 
N-palmitoylethanolamine (PEA) and N-oleoylethanolamine (OEA), which contain palmitic 7 
 
(PA) and oleic (OA) fatty acids respectively are structural moieties  (Pacher, Batkai et al. 
2006). The family of N-acylethanolamides (NEA) are usually considered, on the basis of their 
structure and mode of action as eCB analogues, as they do not bind with high affinity to CB 
receptors but e.g. can potentiate anandamide responses by enhancing the binding capacity of 
anandamide  to  CB1  (Pacher,  Batkai  et  al.  2006;  Pertwee  2010).  Anandamide  has  higher 
affinities to CB1 than to CB2 (Ki(CB1 vs. CB2)= 89 vs. 371 nM, reviewed by (Hohmann 
2002)), acting on both receptors as a partial agonist (Hillard 2000; Pertwee and Ross 2002). 
Furthermore,  anandamide  has  also  been  shown  to  be  an  agonist  at  the  pro-nociceptive 
transient vanilloid (TRPV1) receptor (Zygmunt, Petersson et al. 1999; Smart, Gunthorpe et al. 
2000). Interestingly, the CB1 receptor has an extracellular binding site (Shire, Calandra et al. 
1996) whereas the TRPV1 agonist binds intracellular (Jung, Hwang et al. 1999). This suggests 
that anandamide might regulate anti- and pro-nociceptive effects depending on the activation 
sites. The uptake of NEA, especially of anandamide into the cell, is still in discussion. A 
broad  array  of  anandamide  transporters  are  suggested  as  well  as  the  permeability  of  cell 
membranes to anandamide, which is not clarified yet and was recently summarized by Fowler 
in  2012 (Fowler 2012).  However, recently the assumption of bidirectional trafficking of eCB 
is  strengthened  by  evidence  that  shows  indirectly  a  membrane  target  for  eCB  with  an 
arachidonoyl chain in U937 cells (Chicca, Marazzi et al. 2012). 
Anandamide was shown to be generated by neurons in the brain (Di Marzo, Fontana et al. 
1994; Giuffrida, Parsons et al. 1999) and DRGs (van der Stelt, Trevisani et al. 2005) as well 
as in macrophages, microglia, astrocytes (Varga, Wagner et al. 1998; Walter, Franklin et al. 
2002; Carrier, Kearn et al. 2004) and in the vascular endothelium (Hillard 2000; Liu, Gao et 
al. 2000). 
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The  two  main  endocannabinoids  are  N-arachidonoylethanolamine  (anandamide,  AEA)  and 
2-arachidonoylglycerol (2-AG). Belonging to the group of N-acylethanolamines, like anandamide, 
N-oleoylethanolamine  (OEA)  and  N-palmitoylethanolamine  (PEA)  are  members  of  the 
endocannabinoid family. Adapted and modified from Ueda et al., 2010) 
 
The endocannabinoid 2-AG is released from post-synaptic neurons and acts retrograde on 
pre-synaptic neurons to modulate cellular signaling (Katona, Urban et al. 2006). 2-AG acts as 
full agonist at CB1 and CB2 and is the most potent agonist toward both CB receptors (Hillard 
2000; Savinainen, Jarvinen et al. 2001). The Ki values of 2-AG are  472 ± 55 nM at CB1 and 
1400 ± 172 nM at CB2, respectively (Mechoulam, Ben-Shabat et al. 1995). 2-AG is generated 
by immune cells, microglia, astrocytes and by neurons (Stella, Schweitzer et al. 1997; Walter, 
Dinh et al. 2004). The concentration of 2-AG in brain tissue is approximately 200-fold higher 
than the concentration of anandamide. Both eCB are distributed in the following brain areas: 
highest  in  brainstem,  striatum  and  hippocampus  and  lower  in  cortex,  diencephalon  and 
cerebellum (Bisogno, Berrendero et al. 1999). 
 
Figure 1.1  Endocannabinoids  9 
 
1.4  Endocannabinoid synthesis and degradation 
Control  of  CB  receptor  activation  is  determined  by  eCB  synthesising  and  hydrolyzing 
enzymes.  Due  to  the  lipophilic  character  of  eCB,  they  are  synthesised  on  demand  from 
precursor molecules which are stored in the cell membrane (Di Marzo, 1994). Two enzymatic 
steps  are  required  for  NEA  synthesis,  the  first  of  which  is  N-  acylation  of 
phosphatidylethanolamine (PE) by the calcium dependent N-acyltransferase (NAT). The acyl 
group of a glycerophospholipid is transferred from the sn-1 position to the amino group of the 
PE.  Then,  NEA  and  phosphatidic  acid  are  formed  by  hydrolysis  of  N-arachidonoyl  PE 
through  the  N-  acylphosphatidylethanolamine-selective  phospholipase  D  (NAPE-PLD), 
which limits the biosynthesis of NEA by its availability (Sugiura, Kobayashi et al. 2002; 
Okamoto, Morishita et al. 2004). Alternatively, direct synthesis of NEA from arachidonic acid 
and ethanolamine has also been described (Ueda, Kurahashi et al. 1995), as evidence exists 
that anandamide tissue levels remained unchanged in NAPE-PLD knockout mice compared to 
wild-type animals (Leung, Saghatelian et al. 2006).  
Generally, NEA are signaling transmitters with a short half-time as  they  are quickly  and 
selectively  degraded.  The  best  characterised  enzyme,  fatty  acid  amide  hydrolase  (FAAH) 
degrades  NEA,  favoring  anandamide  (Cravatt,  Giang  et  al.  1996;  Ueda  2002).  FAAH 
degrades NEA intracellularly to arachidonic  acid  and ethanolamine  (Cravatt, Giang et  al. 
1996; Ueda 2002). The optimal function of FAAH is around a pH of nine in vitro (Bisogno, 
De Petrocellis et al. 2002; Ueda 2002) and is found in rat neuronal cells (Di Marzo, Fontana et 
al. 1994). More recently, FAAH has been reported also in adult rat DRG, sciatic nerve and 
spinal cord (Lever, Robinson et al. 2009).  
Another  hydrolyzing  enzyme  of  NEA  is  N-acylethanolamide-hydrolyzing  acid  amidase 
(NAAA), which was recently discovered with a preference for poly unsaturated fatty acids 
like PEA (Ueda, Tsuboi et al. 2010). There is no sequence homology between NAAA and 10 
 
FAAH, while rat, mouse, and human NAAAs show high homology (33–34% identity and 
70% similarity at amino acid level over their entire length) with acid ceramidases of the same 
respective animal species (Ueda, Tsuboi et al. 2010). The optimal reaction of NAAA occurs at 
pH of four to five, indicating NAAA cleavage only after the transportation from the Golgi 
apparatus to endosomes/lysosomes (Ueda, Tsuboi et al. 2010). The pH profiles of NAAA and 
FAAH differ from each other and can be used to differentiate the activities of these two 
enzymes (Sun, Tsuboi et al. 2005). Regarding substrate specificity, NAAA can hydrolyse 
various NAE with C12–C20 fatty acids. PEA is the most active substrate of NAAA (Ueda, 
Yamanaka et al. 2001; Tsuboi, Sun et al. 2005). The activity of NAAA with anandamide was 
less sensitive and NAAA was inactive towards 2-AG, unlike FAAH (Ueda, Tsuboi et al. 
2010).  
 
 
 
 
 
 
 
 
 
The major synthesising pathway involves NAPE-PLD and FAAH and NAAA as the main hydrolyzing 
enzyme. (Adapted and modified from Wang and Ueda, 2009) 
 
 
Figure 1.2   Schematic drawing of the synthesis and hydrolysis of anandamide  11 
 
Sn-1-diacylglycerol lipase alpha (DAGL) is the primary biosynthetic enzyme of 2-AG, found 
at the post-synapse of neurons (Bisogno, Howell et al. 2003).  
2-AG  can  be  synthesised  from  inositol  phospholipids  or  phosphatidylcholine  by  the 
phospholipase C and subsequently by DAGL. 2-AG might also be generated through the 
combined actions of phospholipase A1 and phospholipase C (Stella, Schweitzer et al. 1997; 
Sugiura, Kobayashi et al. 2002; Bisogno, Howell et al. 2003).  
The principal 2-AG hydrolyzing enzyme is monoacylglycerol lipase (MAGL), ascribed for 
85% of total 2-AG hydrolysis, and was unable to metabolize anandamide (Dinh, Carpenter et 
al. 2002; Blankman, Simon et al. 2007). MAGL has an optimum pH of 8 and was found on 
membranes as in cytosolic fractions (Ghafouri, Tiger et al. 2004). Homology of mouse and 
human MAGL was greater than 80 % (Karlsson, Reue et al. 2001). Further studies suggested 
that  the  serine  hydrolase  α-β-hydrolase  domain  12  (ABHD12)  is  highly  expressed  in 
microglia and accounts for approx. 9 % of total brain 2-AG hydrolysis (Savinainen, Saario et 
al. 2012). ABHD12 was suggested as adequate MAGL analogue for brain microglia as well as 
in related cell types of peripheral tissues (Fiskerstrand, H'Mida-Ben Brahim et al. 2010). It 
was also suggested that FAAH was able to hydrolyse 2-AG into arachidonic acid and glycerol 
(Sugiura, Kobayashi et al. 2002). However, in FAAH knockout mice 2-AG levels remained 
stable (Lichtman, Hawkins et al. 2002) and selective FAAH inhibitors failed to enhance 2-AG 
levels (Kathuria, Gaetani et al. 2003).  
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2-AG acts retrograde, synthesised from DAGL at the post-synapse, towards the pre-synapse, where 
2-AG is hydrolysed by MAGL. Adapted and modified from Wang and Ueda, 2009) 
 
1.5  Modulative properties of (endo)cannabinoids in neuronal degeneration 
Central nervous system (CNS) damage resulting from the acute lesion and the magnitude of 
secondary damage determines the outcome of individual neurological impairments. The most 
common neuronal injuries like SCI, TBI or stroke include long-range projections destruction. 
Although the lesion site might be regional restricted and moderate, healthy neuronal tissue 
can be destroyed despite not being involved in the initial lesion. The period after the initial 
insult includes the so called secondary damage, lasting from hours to weeks, and may lead 
together with the first traumatic source to persistent clinical and social disabilities for the 
patients (Blight 1985; Signoretti, Vagnozzi et al. 2010). Secondary damage is associated with 
different inflammatory and cell activating factors as neuronal cell death, reactive astrogliosis 
Figure 1.3   Schematic drawing of the 2-AG metabolism  13 
 
and  microglia  proliferation  and  activation  (Dumont,  Okonkwo  et  al.  2001;  Yakovlev  and 
Faden 2004; Faden and Stoica 2007).  
In the healthy organism eCB are expected to maintain basic physiological processes, sustained 
by  the  constitutive  levels  of  eCB  in  the  organism.  However,  in  pathologic  changes 
tremendous  alteration  in  eCB  concentrations  was  seen  (Mackie  2006).  This  led  to  the 
discovery that the eCBS possess the potency to favor functional sustainment and cellular 
repair.  Still,  the  eCBS  is  one  of  many  different  systems  reflecting  a  major  modulating 
signaling  machinery  influencing  neuronal  damage  and  leading  to  either  destructive  or 
protective results (Piomelli 2003). Understanding the changes in the eCBS during pathologic 
conditions, allows to influence and possibly recovering the system. There also exists evidence 
in vitro and in vivo that the eCBS modulates embryonic and adult neurogenesis and neural 
progenitor proliferation (Aguado, Monory et al. 2005; Jiang, Zhang et al. 2005; Hill, Kambo 
et al. 2006). In the present paragraph the known literature of the eCB, also investigated in the 
present dissertation, and their influence on CNS diseases will be presented.  
 
N-ethanolamines (NEA) 
In several reports enhanced anandamide levels have been detected after various pathological 
events, as well as in human studies (Hansen, Schmid et al. 2001; Maccarrone, Gubellini et al. 
2003; Marsicano, Goodenough et al. 2003). Elevated anandamide levels were measured in the 
cerebrospinal  fluids  of  patients  with  Parkinson  disease  or  after  stroke  and  were  directly 
associated with brain damage (Schabitz, Giuffrida et al. 2002; Pisani, Fezza et al. 2005). 
Anandamide protected in vitro cerebral rat cortical neurons from ischemia (Sinor, Irvin et al. 
2000), indicating a compensatory mechanism to brain damage. Investigations on organotypic 
hippocampal slice cultures described no protective effect of anandamide and THC in dentate 
gyrus neurons (Kreutz et al., 2007). N-arachidonoyl dopamine (NADA) and PEA reduced the 14 
 
number of degenerating neurons. It was shown that NADA activated CB1 and PEA activated 
PPARα  in  microglia  and  neurons  to  restrict  neuronal  damage  (Kreutz,  Koch  et  al.  2009; 
Grabiec, Koch et al. 2011; Koch, Kreutz et al. 2011; Koch, Kreutz et al. 2011). Furthermore, 
anandamide as a CB1 agonist is able to decrease NO release and reduce over-activation of 
microglia  by  down-regulation  of  MAPK  through  mitogen-activated  protein  kinase 
phosphatase-1  (MKP-1)  induction  (Dommergues,  Plaisant  et  al.  2003;  Eljaschewitsch, 
Witting et al. 2006). However, Stella and his group found an increase in microglia motility by 
anandamide in BV-2 cells (Franklin, Parmentier-Batteur et al. 2003) and neurotoxic events 
like ischemic conditions or glutamate supplementation induced enhanced anandamide and 
PEA levels, demonstrating neuroprotective properties under both conditions (Rodriguez De 
Fonseca,  Gorriti  et  al.  2001;  Conti,  Costa  et  al.  2002;  Koch,  Kreutz  et  al.  2011).  One 
underlying mechanism seems to be an enhanced receptor binding capacity of  anandamide not 
only  at  the CB1 receptor but  also at the vanilloid receptor, due to decreased anandamide 
hydrolysis caused by increased PEA levels, which represents the so called entourage effect 
(De Petrocellis, Davis et al. 2001). Further, PEA is reported to protect neurons via activation 
of PPARα in neurons, microglia (Koch, Kreutz et al. 2011) and astrocytes (Raso, Esposito et 
al.  2011).  PPARs  are  nuclear  membrane-associated  transcription  factors  belonging  to  the 
nuclear receptor family which exert anti-inflammatory properties in brain injury (Straus and 
Glass 2007). OEA, as the third N-acylethanolamine, is suggested as a modulator of satiety, 
inflammation, lipid metabolism and antinociceptive effects, due to its activity at receptors 
such as TRPV1, GPR119 or PPAR gamma (Rodriguez De Fonseca, Gorriti et al. 2001; Fu, 
Gaetani et al. 2003; Suardiaz, Estivill-Torrus et al. 2007; Thabuis, Tissot-Favre et al. 2008). 
Neuroprotective  properties  mediated  by  OEA  were  seen  in  dopaminergic  neurons  in  the 
substantia nigra after application of 6-hydroxidopamine in rats simulating a parkinson model 
(Galan-Rodriguez, Suarez et al. 2009). Enhanced OEA levels were found to reduce microglia 15 
 
activation  (Coffey,  Perry  et  al.  1990;  Topper,  Gehrmann  et  al.  1993),  however  no  direct 
comparison of AEA and OEA to stimulate microglia was performed.  
 
2-Arachidonoylglycerol 
2-AG is proposed to reduce excitotoxic damage by acting as a retrograde neurotransmitter 
decreasing  neuronal  firing  (Katona  and  Freund  2008).  GABAergic  interneurons  are  also 
involved in long term depression of excitation (Peterfi, Urban et al. 2012). NMDA provokes 
presynaptic Ca
2+ accumulation, which is one of the early post-injury events leading to the 
activation of 2-AG (Piomelli, Beltramo et al. 1998) and subsequently to the involvement in 
analgesia  and  anti-inflammation  in  the  CNS  (Panikashvili,  Simeonidou  et  al.  2001; 
Panikashvili, Mechoulam et al. 2005; Kreutz, Koch et al. 2009). Pre-synaptic CB1 receptors 
on  nerve  terminals  are  activated  by  2-AG  and  inhibit  glutamate  release,  subsequently 
decreasing excitotoxicity (Katona, Urban et al. 2006). 
After  TBI,  glutamate  is  released  and  leads  to  ROS  production  within  minutes  and  hours 
(Chan, Doctor et al. 2001) and inflammatory cytokine release initiates brain inflammation 
(Shohami, Ginis et al. 1999; Ziebell and Morganti-Kossmann 2010). In vivo models of closed 
head injury and focal ischemia in mice reported intrinsic elevated 2-AG levels after 4 and 1 to 
24 hours post lesion (Panikashvili, Simeonidou et al. 2001; Degn, Lambertsen et al. 2007). 
2-AG administration decreased edema formation, reduced blood brain barrier permeability 
and the production of TNF alpha, IL-1β, IL-6 and NO. Also the general survival and health of 
the treated mice were increased after 2-AG treatment (Panikashvili, Shein et al. 2006; Degn, 
Lambertsen et al. 2007). Only a single administration of 2-AG 1 h after closed head injury 
improved the recovery of mice significantly and was sustained up to 3 month, the end of the 
follow up study (Shohami, Cohen-Yeshurun et al. 2011). 2-AG was as well potent to reduce 
TNF-α levels in LPS stimulated mice in vivo (Gallily, Breuer et al. 2000). In line with TNF- α 16 
 
down-regulation,  2-AG  inhibited  NF-kB  activation  after  TBI  by  CB1  receptor  activation 
(Panikashvili, Mechoulam et al. 2005).  
Another enzyme that is involved in 2-AG regulation is COX-2. COX-2 has been shown to 
catalyze 2-AG oxygenation (Kozak, Rowlinson et al. 2000). Increased 2-AG levels by COX-2 
inhibition showed favored outcomes in a rat model of traumatic brain injury (Gopez, Yue et 
al.  2005).  However,  prolonged  2-AG  stimulation  in  coronal  brain  section  was  found  to 
internalize or down-regulate CB1 receptors (Schlosburg, Blankman et al. 2010). Chronic and 
high 2-AG overload by MAGL inactivation led to compensatory desensitization of CB1 in the 
brain, as CB1 density and functional responses were attenuated (Schlosburg, Blankman et al. 
2010). Administration of 2-AG had consequently no effect on the pathophysiology of TBI in 
CB1-/- mice (Panikashvili, Mechoulam et al. 2005). 
The CB2 receptor, expressed only marginal in healthy brain tissue, can be up-regulated under 
neuroinflammatory  conditions  (for  review:  Stella,  2010).  Microglia  mainly  express  CB2 
receptors and can produce high amounts of 2-AG under pro-inflammatory circumstances by 
the activation of ionotropic P2X7 receptors (Walter, Franklin et al. 2003; Onaivi 2009). 2-AG 
can  also  trigger  microglia  proliferation  in  vitro  and  can  lead  to  reduced  levels  of 
pro-inflammatory cytokines (Carrier, Kearn et al. 2004). Several authors have highlighted the 
importance  of  2-AG  on  the  regulation  of  microglia  during  disease  (Franklin,  Parmentier-
Batteur et al. 2003; Carrier, Kearn et al. 2004; Nunez, Benito et al. 2004). It was also shown 
that  microglia  possess  the  abn-CBD  receptor  and  are  sensitive  to  2-AG  mediated 
neuroprotection  by  enhanced  microglia  migration  via  this  receptor  (Franklin,  Parmentier-
Batteur et al. 2003; Walter, Franklin et al. 2003; Kreutz, Koch et al. 2009).  
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1.6  Organotypic entorhinal hippocampal slice cultures 
The organotypic entorhinal hippocampal slice culture (OHSC) is an excellent model to study 
neuronal plasticity, long-range projections and neuronal damage. The cytoarchitecture and the 
synaptic circuit of the hippocampal formation remain intact and the interaction of neurons, 
astrocytes and microglia can be investigated in an organotypic surrounding, close to that in 
vivo  (Stoppini,  Buchs  et  al.  1991;  Gahwiler,  Capogna  et  al.  1997;  Holopainen  2005).  In 
OHSC neurons, astrocytes and microglia maintain their morphologic characteristics and show 
the  same  structure  as  in  vivo  conditions  (Kunkler  and  Kraig  1997).  The  hippocampal 
formation incorporates the cornu ammonis (CA), the dentate gyrus (DG), the hilusregion (HI), 
the subiculum and the entorhinal cortex (EC). Distinct laminated structures characterise the 
hippocampus,  like  the  stratum  pyramidale  and  the  stratum  granulosum,  composed  of  the 
pyramidal CA region 1-3 (CA1-CA3) neurons and the granule cell layer of the DG (Amaral 
1978; Amaral, Ishizuka et al. 1990; Forster, Zhao et al. 2006). In Fig.4 an overview of the 
following synaptic connection is shown. The neuronal excitation enters from the layers II and 
III of the EC via the perforant pathway (PP) mainly to the outer molecular layer, towards the 
dendrites of the granule cell layer of the DG while some fibers project from the layer III to the 
CA1 region. The mossy fiber pathway extends then towards the CA3 pyramidal cells, creating 
a rich connection between the granular cells and the pyramidal neurons of the CA3 region. By 
the Schaffer collaterals, the excitation is led from the CA3 region to the CA1 pyramidal 
neurons and the loop is made back to the EC. Axons leave the hippocampus via the subiculum 
back to the EC (Coulter, Yue et al. 2011).  
The  hippocampal  circuit  is  excitatory  in  nature  and  uses  glutamate  as  its  primary 
neurotransmitter (Lothman, Bertram et al. 1991) while the final output of this excitatory loop 
is  modulated  and  fine-tuned  by  the  inhibitory  GABAergic  interneurons  at  different  steps 
(Staiger, Zilles et al. 1996). Recent studies showed that the connection fibers from the EC are 18 
 
also connected directly to the entire CA 1-3 region, although in a lesser extent than to the DG 
(Coulter, Yue et al. 2011). OHSC in general are made according to the method published by 
Stoppini et al., (1991). 
 
 
 
 
 
The trisynaptic pathway signal propagates from the layer II of the entorhinal cortex (EC) to the dentate 
gyrus (DG) through the perforant path (PP). DG projects to CA3 via mossy fibers. CA3 neurons 
interconnect via a recurrent network to the CA1 through the Schaffer collaterals and back to the EC. 
The hippocampus contains another excitatory input, called the temporoammonic pathway, in which a 
signal propagates from layer III of EC directly to CA1 distal dendrites. (Figures adapted and modified 
from Amaral and Witter, 1989 and Ramòn y Cajal, 1911) 
 
 
 
CA3 
Figure 1.4  Illustration of a horizontal slice of the hippocampal formation  19 
 
OHSC are used in the present dissertation due to their unique organotypic preservation. After 
preparation  of  OHSC  the  tissue  re-organizes  and  obtains  a  stable  structure  of  functional 
neurons, astrocytes and microglia after five days in vitro.  Therefore this model is qualified to 
investigate cellular interaction without influence of the entire organism. The insights can then 
be applied for specific testing under in vivo conditions.  
 
Neuronal damage in OHSC 
OHSC are mostly used to investigate pharmacological compounds or to study neuronal cell 
damage in vitro due to the maintenance of functional cellular connections. Microglia become 
highly activated after neuronal insults but can hardly be studied in vitro, as single microglia 
cultures are difficult to maintain and their behavior changes depending on culture conditions. 
In  cultured  OHSC  microglia  regain  their  normal  morphology  and  display  a  healthy 
surrounding like under in vivo conditions.  
 
Long range projection transection 
Disruption of long range projection fibers causes detrimental functional deficits. Projection 
fibers connect developmentally distinct brain areas and allow highly specialized motor but 
also mental functions. Disconnection of the originating and target areas is often a result of 
CNS pathologies like SCI, TBI or stroke. The neuroprotective properties of eCB, involving 
analgesia and anti-inflammation in the CNS but also in the periphery, might therefore also be 
involved in fiber damage. OHSC offer a system to study long range projection fibers as they 
exist in spinal cord and other important areas of the CNS. Here, the perforant pathway was 
used to investigate the precise regulation of eCB after fiber damage. The perforant pathway 
fibers originate in the EC and terminate in the molecular layer of the DG, allowing the precise 
dissection of the projecting fiber tract (Stoppini, Buchs et al. 1991; Deller 1997; Frotscher, 20 
 
Heimrich et  al.  1997; Ramirez 2001; Kovac, Kwidzinski et  al.  2004). Transection of the 
perforant pathway (PPT) is a well-accepted tool to gain insight to inflammatory processes, not 
only at the lesion site but also in the surrounding and connected tissue.  
 
Excitotoxicity 
Excitotoxic lesion is the most frequent neuronal damage used in OHSC, either by kanaic acid 
or N-Methyl-D-Aspartat (NMDA). Increased excitation provokes neuronal cell death and is 
one of the main causes to acute and delayed cell death that is seen in vascular, traumatic and 
degenerative diseases in the CNS (Choi, Koh et al. 1988). Activation of NMDA receptors 
leads to intracellular Ca
2+ entry promoting various effects like nitrogen monoxide increase, 
cytoplasm and nuclear processes that finally mediate cell death. The CA3 pyramidal neurons 
are together with the CA1 neurons the most vulnerable cell type of the hippocampal formation 
followed by the DG granule cells. (Holopainen, Lauren et al. 2001; Kristensen, Noraberg et 
al. 2001).  
 
1.7  Aim of the research  
The involvement of the eCB regulation within the different glial cells during neuronal insults 
and the temporal alteration of eCB are still unknown.  However, the involvement of the eCBS 
in various processes of neuronal insults is indicated as described previously. Here, the precise 
temporal regulation of the eCB after neuronal  excitotoxicity and lesion of  the long-range 
projection in the hippocampus is investigated. OHSC were used to study the different lesion 
models as the anatomical structure allows differentiating neuronal subpopulations and site-
specific effects. The perforant pathway, as long-range projections, allows to investigate the 
differentially (anterograde or retrograde) lesioned regions. The EC, DG, and the CA1 are 
included in the present study. 21 
 
The excitotoxic lesion model of OHSC induces a neuronal inflammation initiated by neuronal 
over-stimulation. In the investigated areas of OHSC, neuronal populations displaying diverse 
vulnerabilities (from low to high; CA1, DG, EC) to excitation can be differentiated. Thus, the 
eCB regulation of differentially lesioned neuronal populations is determined.  
 
 
 
 
 
 
 
The differentiated regions in OHSC, which are analysed after PPT and excitotoxic lesion  in the 
present study. Entorhinal cortex (EC), dentate gyrus (DG), cornu ammonis region 1 (CA1) 
 
The main synthesising and hydrolysing enzymes of the eCB were studied up to 72 hours after 
excitotoxicity and PPT in OHSC as well. The intrinsic enzymatic regulation is determined to 
investigate the involved cell populations in eCB regulation. Moreover, the respective cell type 
being responsible for eCB metabolism, namely neurons, microglia or astrocytes, are analysed 
in primary cell cultures as well as in lesioned OHSC to clarify their ability to regulate eCB 
and their synergistic effects in tissue culture. Like other CB receptors which were shown to be 
involved  in  protective  mechanisms  after  neuronal  lesion,  the  possible  CB3  GPR55  is 
Figure 1.5  Dissected areas of OHSC  22 
 
investigated  in  excitotoxically  lesioned  OHSC  on  its  impact  on  neuronal  protection  after 
excitotoxic lesion. 
 
 
 
 
 
 
 
 
 
In the present dissertation the shown cell types and their involvement in endocannabinoid regulation 
are investigated. 
 
 
 
 
 
 
Figure 1.6   Schematic drawing of cell types present in OHSC  23 
 
Hypotheses: 
A.  Are NEA intrinsically and cell-dependently regulated after PPT in rat OHSC? 
 
B.  Is 2-AG intrinsically and cell-dependently regulated after PPT in rat OHSC? 
 
C.  Is 2-AG an overall neuroprotective modulator after excitotoxicity and PPT? 
 
D.  Does GPR55 excert neuroprotective effects in excitotoxically lesioned OHSC ?  
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2.  Materials and Methods 
2.1  Materials 
All  substances  used  were  treated  following  producers  recommendations.  Substances  were 
dissolved in DMSO or ethanol and stored at -20°C (Tab. 2.1). The final concentration of 
DMSO or ethanol was 0.1% (v/v) or below. To exclude any interference of the used solvents, 
equivalent concentrations of DMSO and ethanol were used for control experiments. 
 
Table 2.1  Canabinoid/GPR55 agonists and antagonists and deutered standards used for the 
experiments 
 
substance  specification  concentration  solvent  manufacturer 
AM281  synthetic CB1 
antagonist/inverse 
agonist 
0.1 µM 
10 µM 
DMSO  Tocris (Cat no. 
1115) 
JZL184  MAGL inhibitor  10 µM  DMSO  Gift from  
J. Long (La 
Jolla, USA) 
L-alpha-
Lysophosphatidyl
-inositol (LPI) 
GPR55 agonist  0.01, 0.1, 1.0, 
10 µM 
DMSO  Sigma- Aldrich 
(Cat no. L7635) 
WIN-55,212-2 
mesylate 
CB1 and CB2 agonist  1 µM  ethanol  Tocris (Cat no. 
1038) 
AEA-d8  Arachidonoyl 
ethanolamide-d8 (AEA-
8) contains eight 
deuterium atoms at the 
5, 6, 8, 9, 11, 12, 14, 
and 15 positions 
5 ng/ml   ethanol  Cayman 
Chemical (Cat 
no. 390050) 
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Continue of Tab 2.1: Canabinoid/GPR55 agonists and antagonists and deutered standards used for the 
experiments 
substance  specification  concentration  solvent  manufacturer 
PEA-d4  Palmitoyl 
ethanolamide-d4 (PEA-
d4) contains four 
deuterium atoms at the 
7, 7', 8, and 8' positions 
10 ng/ml   ethanol  Cayman 
Chemical (Cat 
no. 10007824) 
OEA-d2  Oleoyl ethanolamide-d2 
(OEA-d2) contains two 
deuterium atoms at the 
11 position 
20 ng/ml  ethanol  Cayman 
Chemical (Cat 
no. 10007823) 
2-AG-d5   2-Arachidonoyl 
glycerol-d5 (2-AG-d5) 
contains five deuterium 
atoms at the 1, 1, 2, 3, 
and 3 positions of the 
glycerol moiety 
10 ng/ml  ethanol  Cayman 
Chemical (Cat 
no. 362162) 
1-AG-d5  1-Arachidonoyl 
glycerol-d5 (1-AG-d5) 
contains five deuterium 
atoms at the 1, 1, 2, 3, 
and 3 positions of the 
glycerol moiety 
10 ng/ml  ethanol  Cayman 
Chemical (Cat 
no. 362152) 
 
 
Antibodies were stored following manufacturers recommendations and applied with the 
dilution factor tested  individually for each antibody (Tab. 2.2) 
 
 
 
 26 
 
Table 2.2  Antibodies and stainings listed in alphabetic order 
 
antibody  blocking 
peptide 
dilution 
IHC 
dilution 
WB 
secondary 
AB  
manufacturer 
ß-actin 
monoclonal 
mouse antibody 
directed against 
human 
    1:40 000  anti-mouse 
IgG, 1:4000 
Sigma-Aldrich 
(Cat. no A1978)  
CB1 guinea pig 
polyclonal 
antibody against 
murine  
  1:100  1:2000  Goat anti 
guinea pig 
568 
Frontier Science, 
(Cat no. CB1-G P-
Af530-1) 
DAGL alpha 
rabbit polyclonal 
antibody against 
human 
  1:200  1:1000  Goat anti 
rabbit 568 
Frontier Science, 
(Cat no. DGLa-
Rb-Af380-1)  
FAAH rabbit 
polyclonal 
antibody against 
human 
FAAH (Cat no 
301600) 
1:200 
 
1:1000  Goat anti 
rabbit 568 
Cayman Chemical 
(Cat no. 101600) 
GFAP 
monoclonal 
mouse antibody 
5% (v/v) Roti  1:200 
 
  Goat anti 
mouse 633 
BD Pharmingen 
(Cat no. 556330) 
Hoechst 33342    1:50 000    405   Sigma-Aldrich 
(Cat no. B2261) 
IsolektinB4 
Griffonia 
simplicifolia (IB4) 
  1:50 
 
  FITC 
conjugated 
(488) 
Vector Labs  
(Cat no. FL-1201) 
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Continue of Tab 2.2 Antibodies listed in alphabetic order 
 
antibody  blocking 
peptide 
dilution 
IHC 
dilution 
WB 
secondary 
AB  
manufacturer 
MAGL rabbit 
polyclonal 
antibody against 
human 
  1:200    Goat anti 
rabbit 568 
Cayman Chemical 
(Cat no. 100035) 
MAGL rabbit 
polyclonal 
antibody against 
human 
developed by 
K. Mackie`s 
lab 
 
 
1:200  anti-rabbit, 
1:1000 
gift from K. 
Mackie, Indiana, 
USA 
NAAA rabbit 
polyclonal 
antibody against 
rat 
developed by 
Ueda`s lab 
1:1000 
 
1:5000  Goat anti 
rabbit 568 
gift from  N. 
Ueda, Kagawa, 
Japan 
NAPE-PLD 
rabbit polyclonal 
antibody against 
human 
NAPE-PLD 
peptide, cat.-
No 10303 
1:200 
 
1:1000  Goat anti 
rabbit 568 
Cayman Chemical 
(Cat no. 10305) 
NeuN mouse 
monoclonal 
antibody  
5% (v/v) Roti  1:200 
 
  Goat anti 
mouse 633 
Millipore  
(Cat no. MAB377)  
Propidium Iodide 
(PI) 
  5μg/ml 
 
  536   Sigma-Aldrich 
(Cat no. 25535-
16-4) 
PPARα rabbit 
polyclonal 
antibody against 
murine 
PPARα, cat.-
No PEP-025 
1:1000  1:1000  Goat anti 
rabbit 568 
Thermo Scientific 
(Cat no PA1-
822A)  
Vglut1 guinea pig 
polyclonal 
antibody 
    1:1000  Goat anti 
guinea pig 
488 
Synaptic Systems  
(Cat no. 135304) 
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The following table shows the buffer solutions used in the experiments. The amounts are 
calculated for one liter of distilled water.  
 
Table 2.3  Main puffers used 
 
Phosphate buffer (PB) 
0,1M (pH 7.4): 
 
 
PB 0,2M (pH 7.4): 
 
 
PBS/Triton:  
 
Na2HPO4                  11,36 g  Na2HPO4                  22,72 g  PBS                                  1 L 
KH2PO4                      2,72 g  KH2PO4                      5,44 g  Triton X-100                  3 ml 
 
PBS (pH 7.4): 
 
 
TBS (pH 7.4) 
 
TBS/Triton 
NaCl                            9,00 g  NaCl                          8,76 g  TBS                                  1 L 
KH2PO4                      0,54 g  Tris                            6,05 g  Tween-20                       3 ml 
Na2HPO4                    2,27 g     
 
 
Gel electrophoresis for western blot analysis was conducted with gels described in table 2.4. 
Further cell and slice culture media as well as western blot buffers are described in Tab. 2.5.  
 
Table 2.4  Gel electrophorese was conducted with following gels 
 
  separating gel  
(7,5 %)  
separating gel  
(12,5 %) 
stacking gel (5 %)  
 
Aqua dest.   7,45 ml  4,95 ml   3,05 ml  
1,5 M Tris-HCl (pH 8,8) 
+SDS  
3,75 ml  3,75 ml   - 
1,5 M Tris-HCl (pH 6,8) 
+SDS  
-  -   1,25 ml  
Acrylamid/Bis 30%   3,75 ml  6,25 ml   650 µl l 
10% Ammoniumpersulfat   45 µl  45 μl   25 μl  
TEMED     10 µl  10 μl   10 μl  29 
 
 
Table 2.5  Culture media and Western Blot buffers 
 
Slice culture media (pH 7.4) 
   
Cell culture media 10 % 
and 2 % 
Minimal essential Media 
(MEM, Gibco)        50 % (v/v) 
Streptomycin (sigma-
Aldrich)               0.1mg/ml 
DMEM                  88% (v/v) 
Hanks’ balanced salt solution 
(HBSS, Gibco)       25 % (v/v) 
Penicillin (sigma-Aldrich) 
                            100 µg/ml 
Glutamine               1 % (v/v) 
Normal horse serum (NHS, 
Gibco)                    25 % (v/v) 
Ascorbic acid (Sigma-
Aldrich)               0.8 µg/ml 
Penicillin                1 % (v/v) 
Glutamine (Braun)                        
                                  2 % (v/v) 
Insulin (Boehringer)                            
                                1 µg/ml 
Feutal bovine serum 
                              10% (v/v) 
                           or 2 % (v/v) 
Glucose (Braun)      1.2 mg/ml     
 
Lysis buffer 
 
Elektrophorese buffer 
 
Transferbuffer 
Tris                               80 mM  Tris                                 3 g  Tris                                   3 g 
Sodium dodecylsulfate–
polyacrylamide (SDS)                                       
                                     70 mM 
Glycin                       14,4 g  Glycin                          14,4 g 
Saccharose                 300 mM  10 % SDS                  10 ml    10 % SDS                    10 ml    
Sodium orthovanadate (SOV) 
                                       3 mM 
Aqua dest.                      1 L  Methanol                    200 ml 
Phenylmethylsulfonyl fluoride 
(PMSF)                       0.5 mM 
  Aqua dest.                800 ml 
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2.2  Methods 
2.2.1  Cell culture 
 
Ethic statement 
All animal experiments have been approved by the ethics committees of the German federal 
states of Hessen or Saxonia and were performed in accordance with the Policy on Ethics and 
the Policy on the Use of Animals in Neuroscience Research as approved by the European 
Communities Council Directive (89/609/EEC) amended by the directive 2010/63/EU of the 
European Parliament and of the Council of the European Union on the protection of animals 
used for scientific purposes. The animals were hold in a 12 hour light, 12 hour dark cycle with 
water and standard food ad libitum. The animals were decapitated at postnatal day 0-2 (p 0-2) 
for cell cultures and at p8 for OHSC.  
 
Primary cell cultures 
Primary cultures of hippocampal neurons were prepared using a modified method originally 
described by Brewer and colleagues under aseptic conditions (Brewer, Torricelli et al. 1993). 
Wistar rat pubs (p0) were decapitated and brains were prepared by removing the skin and the 
cranium with small scissors. Subsequently, brains were placed carefully with forceps into a 
solution of ice-cold HBSS. The hippocampi were dissected with an applicator and placed in 
Neurobasal Medium (Gibco) containing BSA (Sigma-Aldrich) and papain (1 mg/ml, Sigma-
Aldrich) for 20 min at  37 °C. Then neurons  were isolated by tissue dissociation  using a 
Pasteur pipette until tissue homogenisation. The obtained homogenate was centrifuged for 
10 min  (45  g)  and  plated  onto  poly-L-lysine-coated  coverslips.  Cells  were  maintained  in 
Neurobasal  medium  supplemented  with  B-27  (Gibco),  GlutaMAX  (Gibco)  and 
penicillin/streptomycin at 37 °C in a humidified atmosphere with 5 % (v/v) CO2 for 2 weeks.  31 
 
Primary microglia and astrocyte cell cultures were isolated from cerebral cortices of p 1-2 
neonatal Wistar rats. Brains were removed as described above and placed into a solution of 
ice cold HBSS. The meninges were removed with thin forceps and after 5 min incubation 
with Ca
2+/Mg
2+-free HBSS, containing trypsin (4mg/ml, Boehringer) and DNAse (0.5mg/ml, 
Worthington, Bedford, MA, USA) the cerebral cortices were dissociated. Cells were plated 
into poly-L-lysine (Sigma-Aldrich) coated 75 cm
2 tissue culture flasks (Falcon) containing 
10 %  cell  culture  media.  To  obtain  a  proper  glial  culture  astrocytes  and  microglia  were 
cultured for 10 days in a mixed culture. The cell culture media was changed every other day. 
Culture media is optimised for glial cells, neurons do not survive the cultivation procedure, 
using that procedure astrocyte-microglia cultures were obtained. 
Microglia were isolated from the astrocytic monolayer by gentle shaking of the culture flasks 
with fresh culture media for 20 min. The microglia in the culture media was centrifugated for 
5 min at 150 g. The supernatant was removed and the obtained cells were cultured in 2 % cell 
culture media into 6 or 24-well dishes coated with poly-L-lysine one day prior to experiments. 
Astrocyte cultures were obtained after microglia were removed for at least three times by the 
procedure described above. The astrocytes were then washed with serum free media and were 
incubated with 2 ml of trypsin/EDTA for 5 min. Trypsin was stopped with 10 % cell culture 
media and cells were transferred in a 15 ml falcon tube (Greiner) for centrifugation for 5 min 
at 150 g. Supernatant was removed and the obtained cells were cultured in 2 % cell culture 
media. One day prior to all experiments, primary cultures of astrocytes were transferred into 
6 or 24-well dishes coated with poly-L-lysine. 
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Organotypic entorhinal hippocampal slice cultures 
OHSC were prepared from 8-day old Wistar rats. Animals were decapitated and the brains 
were dissected under aseptic conditions. Brains were removed as described above and placed 
into a solution of ice cold HBSS. Subsequently the cerebellum and the frontal lobe were 
removed with a vertical cut using a scalpel and brains were placed in 4 °C minimal essential 
medium (MEM) containing 1 % (v/v) glutamine (Gibco). The brains were cleaved with tissue 
adhesive (Histoacryl,  Braun, Melsungen, Germany) to  a vibratome dish prepared with  an 
aseptic agar block to stabilise the brains during the slicing procedure. The vibratome dish with 
the  brain  was  placed  in  ice-cold  MEM  on  a  sliding  vibratome  (Leica  VT  1200S,  Leica 
Microsystems  AG,  Wetzlar,  Germany),  which  was  used  to  cut  the  brain  horizontally  in 
350 µm-thick  slices.  The  hippocampi  were  dissected  under  a  binocular  (Zeiss)  and  were 
immediately  placed  on  cell  culture  inserts  (pore  size  0.4  µm;  Millipore,  Schwalbach/Ts., 
Germany) for 6-well culture dishes (Falcon, BD Biosciences Discovery Labware, Bedford, 
MA). The dishes contained 1 ml slice culture medium per well. OHSC were cultured at 35 °C 
in a fully-humidified atmosphere with 5 % (v/v) CO2. The culture medium was changed every 
second day. 
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2.2.2  Neuronal lesion models 
 
Perforant Pathway Transection  
The PPT was mechanically set on day in vitro (div) 6 by use of a disposable ophthalmic 
scalpel  equipped  with  a  stainless  steel  blade  (Feather,  Osaka,  Japan).  Under  a  binocular 
(Zeiss, Jena, Germany), PPT was performed within OHSC through the perforant pathway 
following the sulcus between the hippocampus and the entorhinal cortex (EC) as visualised in 
Fig 2.1. The EC, the DG and the CA1 regions were dissected 0, 1, 6, 12, 24, 48 or 72 hours 
post lesion (hpl).  
 
 
 
 
 
 
 
 
 
 
 
The black line indicates the transection of the axons originating from layers II and III of entorhinal 
cortex (EC) and projecting to the outer molecular layer (oml) of the dentate gyrus (DG). The areas of 
EC, DG and cornu ammonis (CA)1 were dissected as visualised by the open  cycles. OHSC were kept 
in culture for 6 days before PPT was set and tissue of the highlighted areas was collected 1 h, 6 h, 
12 h, 24 h, 48 h and 72 h post lesion. Bar= 500 µm. 
 
 
Figure 2.1   Overview of the perforant pathway transection (PPT) in OHSC 34 
 
 
 
 
 
The PPT is set between the EC and the DG to cut all the connecting axonal fibers from the EC to the 
outer molecular layer of the DG. The EC, DG and the CA1 tissue is collected after the respective time 
of interest. 
 
 
Excitotoxic lesion and treatment protocol 
After  OHSC  preparation,  the  tissue  cultures  were  spread  over  the  different  experimental 
groups as described below. The control group was incubated with culture media from div 0 
until  div  9,  the  day  of  fixation.  They  were  used  as  negative  controls.  Substances  were 
supplemented to the culture media at div6 until div 9 to control for effects of the substances 
themselves. Excitotoxic lesion was conducted on div 6. 50 µM NMDA was added to the 
culture media for 4 h. Thereafter, tissue cultures were washed once with culture media and 
cultured until div9 in culture media which was changed every day from the NMDA lesion on. 
This condition was used as positive control.  
 
 
Figure 2.2  Visualisation of the PPT and tissue collection 35 
 
 
 
 
 
 
 
 
 
During  excitotoxic  lesion,  neurons  become  activated  and  intracellular  calcium  and  nitric  oxygen 
become altered, leading finally to cell death through apoptosis and necrosis. The black box indicates 
the area of analysis. DG, dentate gyrus. 
 
LPI and Win55,212 were supplemented to the culture media 120h and 24h before excitotoxic 
lesion  took  place  to  study  preconditioning.  The  treatment  with  LPI  and  Win55,212  was 
applied also during NMDA lesion and also thereafter until div7 or div9. These conditions 
served  to  find  optimal  conditions  for  neuronal  protection  and  to  identify  the  substance 
involvement in secondary damage.  
AM281  is  a  GPR55  agonist  with  less  potency  and  a  CB1  antagonist/inverse  agonist 
(Henstringe, 2011). AM281 was supplemented to OHSC after NMDA lesion with and without 
LPI.  
 
 
 
DG 
Figure 2.3  Excitotoxicity in OHSC by NMDA 36 
 
siRNA transfection  
MAGL gene silencing was carried out using Magl siRNA vs. rat:  
(target sequence: 5’-CAGCGTGCTGTCTCGGAACAA-3’;  
sense strand: 5’-GCGUGCUGUCUCGGAACAATT-3’;  
antisense  strand:  5’-UUGUUCCGAGACAGCACGCTG-3’;  cat.  no.:  SI03067736,  Qiagen, 
Hilden,  Germany).  For  transfection  GeneSilencer  siRNA  transfection  reagent  (Genlantis-
BioCat, Heidelberg, Germany) for 6-well-culture plates were used. The following sequences 
were used for Gpr55 siRNA vs. rat:  
target sequence: 5’- CACGTGGAGTGCGAGAGTCTT-3’;  
sense strand: 5’ CGUGGAGUGCGAGAGUCUUTT-3’;  
antisense strand: 5’-AAGACUCUCGCACUCCACGTG-3’, (cat. no.: SI03004708, Qiagen, 
Hilden, Germany). AllStars Negative Control siRNA (Qiagen) was used as a negative control. 
25 µl culture medium and 5 µl GeneSilencer per well were preincubated for 5-10 min at RT. 
Then 15 µl culture medium was mixed with 25 µl siRNA Diluent and 1 µg siRNA or AllStars 
Negative Control siRNA (per well) and were incubated for 5 min at RT. Next, the transfection 
mix was prepared by combining the diluted GeneSilencer with siRNA mixture and incubated 
for 10 min at RT. The entire mixture was added directly to the hippocampal slice cultures on 
5 div and the slices were cultured in serum-containing medium (1 ml/well). After 24 h culture 
medium was exchanged with standard culture medium. 
 
2.2.3  OHSC staining for determining neuronal death and microglia determination  
To analyse neuronal cell death in the dentate gyrus, the medium of OHSC was supplemented 
with 5 µg/ml propidium iodide (PI) 2 h prior to fixation with 4 % (w/v) paraformaldehyde 
(PFA) (Sigma-Aldrich) in 0.1 M phosphate buffer (PB). PI is a non damaging fluorescent 
stain  that  enriches  in  dead  cell  nuclei  by  adhesion  to  DNA.  At  div9  culture  media  was 37 
 
removed and 4 % PFA was added for at least 4 h, the cultures were washed twice with PB and 
stored in PBS buffer at 4 °C until further handling. Using Isolectin B4 (IB4) combined with 
fluorochrom FITC, microglia were visualised. To achieve this, OHSC were incubated 30 min 
in normal goat serum (1:20 in PBST) followed by an incubation with IB4 ((1:50 in 0,5 % 
(w/v) BSA in PBST) over night. On the next day, OHSC were washed two times for 10 min 
in PBS and once in distilled water and were then embedded with Dako fluorescent mounting 
medium (Dako Diagnostika GmbH, Hamburg, Germany) and stored at 4 °C for at least 4 h. 
To analyse cell death and microglia accumulation z-stacks (2 µm) with 20 fold magnification 
of OHSC were generated by an inverse Zeiss LSM 510 Meta confocal laser scanning system 
(Zeiss,  Göttingen,  Germany).  ImageJ  software  (U.S.  National  Institutes  of  Health, 
http://rsb.info.nih.gov/ij/download.html)  was  used  for  counting  degenerating  PI  positive 
neuronal nuclei in the different EC, DG and CA1 regions.  
 
2.2.4  Endocannabinoid analysis of OHSC by LC-MS/MS 
Tissues of 3 OHSC were pooled, immediately shock frozen in liquid nitrogen and stored at 
-80 °C. Homogenisation was performed on ice to prevent degradation of eCB or internal 
standards. The extraction of eCB was conducted with a 9:1 (v/v) ethylacetate/n-hexan solution 
(Bishay, Schmidt et al. 2010). The tissue was homogenised first in 70 µl ice cold H2O in a 
mixer mill 400 (Retsch, Haan, Germany) for 90 seconds at 25 Hz. As a next step, 20 µl were 
taken away from the homogenates to quantify the protein amount of beta-actin by Western 
Blot analysis (see below). 50 µl of the tissue samples were again homogenised together with 
25 µl of internal standards, 50 µl ethylacetate/n-hexan and 50 µl H2O. After 3 minutes of 
centrifugation at 10.000 g, the organic phase was collected and the extraction procedure was 
repeated. The  ethylacetate phases  were  evaporated under  a  gentle stream  of nitrogen  and 
assimilated in 25 µl acetonitril in glass vials. Finally, 10µl were injected into the LC-MS/MS 38 
 
system  (API,  5000,  AB  SCIEX,  California,  USA).  For  accuracy,  quality  standards  were 
always extracted with the samples. 
The reconstituted samples were analysed for anandamided, OEA and PEA. The respective 
deuterated AEA-d8, OEA-d2 and PEA-d4 were used as internal standards. HPLC analysis was 
performed under gradient conditions using a Luna HST C18 (2) column (100 mm L x 2 mm 
ID, 2.5 µm particle size; Phenomenex, Aschaffenburg, Germany). MS and MS/MS analysis 
was performed on an API 5000 triple quadrupole mass spectrometer with a Turbo V source 
(Applied Biosystems, Darmstadt, Germany) in the negative ion mode. Precursor-to-product 
ion transitions of m/z 346259 for AEA, m/z 35486 for AEA-d8, m/z 32486 for OEA, 
m/z 32686 for OEA-d2, m/z 298268 for PEA and m/z 302258 for PEA-d4 were used for 
the multiple reaction monitoring (MRM) with a dwell time of 70 milliseconds. Concentrations 
of calibration standards, quality controls and unknowns were evaluated by Analyst software 
(version  1.4;  Applied  Biosystems).  Variations  in  accuracy  and  intra-day  and  inter-day 
precision were <15 % over the range of calibration. Endocannabinoid values were expressed 
in  relation  to  ß-actin  levels  obtained  by  Western  Blot  analysis  (Image  J  1.43, 
imagej.nih.gov/ij/download/).  In  each  experiment,  protein  extracts  from  controls  and 
corresponding PPT time matches were run on the same gel to ensure similar conditions for 
both groups. ECB values were then normalised and values obtained from controls were set as 
100 %. Changes after PPT were described in relation to corresponding time controls.  
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2.2.5  Western Blot analysis 
For Western Blot analysis the tissue was collected and immediately stored in lysis buffer at 
-80  °C. Protein  extracts were obtained by  sonication of tissues in  lysis  buffer containing 
80 mM  Tris,  70  mM  SDS,  0,3  M  Saccharose,  3  mM  sodium  orthovanadate  and 0.5 mM 
phenylmethylsulfonyl fluoride (PMSF) at pH 7.4. Cell debris was removed by centrifugation 
for 10 min at 3000 g. Protein concentrations of the supernatants were determined by BCA test 
(Thermo Fisher Scientific, Rockford, USA). Equal protein amount of 5 µg were loaded onto a 
12,5  %  or  7,5  %  (w/v)  sodium  dodecylsulfate–polyacrylamide  (SDS)  gel.  After  gel 
electrophoresis, proteins were electrotransferred to nitrocellulose membranes. After blocking 
non-specific  protein-binding  sites  for  1  h  with  5  %  (w/v)  milk  (Carl  Roth,  Karlsruhe, 
Germany) or 5 % (v/v) Roti-block solution (Carl Roth, Karlsruhe, Germany) in TBST, the 
membranes  were  incubated  over-night  with  the  respective  following  primary  antibodies 
diluted in 5 % (w/v) milk or 5 % (v/v) Roti block in TBST. The next day, membranes were 
washed  three  times  with  TBST  for  10  min  and  the  secondary  horse  radish  peroxidase-
conjugated antibodies (anti-rabbit, 1:1000; cat.-No PI 1000, Vektor laboratories, Burlingame, 
CA; anti-guinea pig 1:1000;cat.-No P0141, DAKO Diagnostika GmbH, Hamburg, Germany 
or anti-mouse IgG, 1:4000; cat.-No CP01, Millipore, Billerica, USA) were added for 1 h. 
Membranes were finally exposed to enhanced chemiluminescence (ECL detection system, 
Millipore) and the signal of bound antibody was visualised with radiographic films (Kodak, 
Stuttgart, Germany). Finally, semiquantification of the immunoreactive bands was performed 
with ImageJ image analysis software. 
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Specificity tests for the antibodies used 
The specificity of the antibodies was tested by preabsorption with the corresponding blocking 
peptides. For preabsorption, each primary antibody was diluted in 5 % (w/v) milk or 5 % (v/v) 
Roti block in TBST and incubated with a five to ten-fold excess (by weight) of its blocking 
peptide for 1 h at room temperature with gentle shaking. Thereafter, the antibody-blocking 
peptide solution was applied to the Western Blot membranes and the subsequent procedures 
followed as in the above described Western Blot protocol. The CB1 antibody was tested on 
CB1 (-/-) knock-out mice (kindly provided by Beat Lutz, Mainz, Germany). 
 
2.2.6  Immunocytochemistry 
The OHSC were fixed with a 4 % (w/v) paraformaldehyde solution in 0.1 M PB for at least 4 
h. After fixation, OHSC were washed in PB and incubated for at least 4 h in 15 % (w/v) 
sucrose,  followed  by  30  %  (w/v)  sucrose,  respectively.  Using  a  cryostat  3050  S  (Leica, 
Wetzlar,  Germany),  the  OHSC  were  sectioned  (14  µm)  and  mounted  on  superfrost 
microscope  slides  (Thermo  Scientific).  To  block  unspecific  binding  sites,  sections  were 
preincubated with normal goat serum for 30 min (1:20 in PBS/Triton) followed by incubation 
with primary antibodies for 16 h in PBS/Triton containing 0.5 % (w/v) bovine serum albumin. 
Binding of the primary antibodies was visualised by means of the ABC method with a biotin-
conjugated anti-rabbit IgG (diluted 1:100; cat-No B7389 Sigma-Aldrich) as the secondary 
antibody, a horseradish  peroxidase (HRP)-conjugated streptavidin complex (diluted 1:100; 
cat.-No  E2886  Sigma-Aldrich)  and  3,  3-diamino-benzidine  as  the  chromogen.  For 
immunocytochemical  characterisation  of  different  cell  populations  within  OHSC,  the 
following primary antibodies were used: NeuN as a neuronal marker, GFAP as a marker for 
astrocytes and IB4 as a marker for microglia. 41 
 
For triple-immunofluorescence staining, the primary antibodies against NAPE-PLD, FAAH, 
NAAA, CB1 or PPARα were combined with IB4 and either with antibodies against NeuN or 
GFAP respectively. After incubation with primary antibodies for 16 h at room temperature, 
sections were washed three times with PBS followed by application of secondary antibodies 
Alexa fluor dye 568 (goat-anti rabbit IgG, 1:500, cat.-No A-11011, Invitrogen) and Alexa 
fluor dye 633 (goat anti-mouse IgG, 1:100, cat.-No A21050, Invitrogen, Karlsruhe, Germany) 
for 1 h. The preparations were finally coverslipped with Dako fluorescent mounting medium 
(Dako) and analysed using a Zeiss LSM 510 Meta confocal laser scanning system.  
 
2.2.7  Semi-quantitative real time PCR 
All  primers  were  synthesised  by  MWG  Biotech,  Eversberg,  Germany  and  diluted  to 
10 pmol/μl. Cells or OHSC were harvested and stored in RTLlater (Qiagen) at -80 °C until 
further  use.  Total  RNA  was  extracted  from  the  cells  using  TRIzol  reagent  (invitrogen) 
according to the manufacturers instructions.  For RNA extraction, the cells and the tissues 
were collected and immediately stored in 50 µl RLTlater at -80 °C until further use. Tissue 
rupture was obtained by sonication 3x 3 sec in 1 ml Trizol reagent (invitrogen) on ice. The 
samples were centrifuged for 10 min at 10.000 rpm at 4 °C. The supernatant was transferred 
into a new Eppendorf tube and 200 µl chloroform were added to obtain RNA. After 3 min at 
room temperature, the tubes were centrifuged at 13.000 rpm for 15 min and the upper phase 
(500 µl) was transferred into a new tube. 600 µl of ice cold isopropanol were added and 
incubated 10 min at RT for protein precipitation.  
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Table 2.6  Primer sequences 
Gene 
product 
(rat)  
mRNA 
accesion 
Nucleotide sequence 5´-3´  °C 
DAGL  NM_0010
05886.1 
sense TGAGCCCCACTGAGGTAGAC 
antisense GGACAGCAGCAACAGCTCTA 
 
61 
MAGL  NM_1385
02.2 
sense: ATATCCTTGGGGCGCATCGA 
antisense: GATGAGTGGCTCGGAGTTGT 
 
57 
GPR55  XM_0010
63474.1 
sense: CTGCCACAAGTGAAGTCC 
antisense: GACCACGAAGACGACAAG 
 
61 
GAPDH  NG_0283
01.1 
sense: ATGGTGAAGGTCGGTGTGA 
antisense: AAGATGGTGATGGGCTTCC 
 
57-
61 
 
After centrifugation for 15 min at 11 000 g, supernatant was discarded and RNA was washed 
with 75 % (v/v) ethanol and dissolved in 20 µl DPC water. RNA measurement was done by 
photometric analysis. The mesomeric structures of purin and pyrimidin that are part of the 
nucleic acid are excited by UV-light. The absorption was measured at 260 nm and 280 nm. 
The quotient of the measured absorption represents the purity of the RNA extracted and must 
be above 1.7 (OD 260/280). Total RNA was immediately reversely transcribed (Superscript 
II, Invitrogen) with oligo(dT) primer cDNA. 50 ng of total RNA were subjected to rtPCR 
using  Platinum-SYBR  Green®  qPCR  Supermix  (Invitrogen).  Oligonucleotide  primers 
(Tab.2.4) were designed with the Primer3 software to flank intron sequences. All primers 
were  synthesised  by  MWG  Biotech,  Eversberg,  Germany  and  diluted  to  10  pmol/μl. 
Quantitative rtPCR was performed by an CFX9 (Bio Rad laboratories, München, Germany) 
using the following protocol: 3 min at 95 °C and 40 cycles of 10 sec at 95 °C and 30 s at 43 
 
57-61  °C.  A  product  melting  curve  was  recorded  to  confirm  the  presence  of  a  single 
amplicon. The correct amplicon size and identity were additionally confirmed by agarose gel 
electrophoresis.  Standard  curves  with  serial  dilutions  of  cDNA  were  generated  for  each 
primer pair to assert linear amplification. Threshold cycle (Ct) values were set within the 
exponential  phase  of  the  PCR.  After  normalisation  to  rodent  glyceraldehyde  3-phosphate 
dehydrogenase (GAPDH) primer, ΔCt values were used to calculate the relative expression 
levels. Gene regulation was statistically evaluated by subjecting the ΔΔCt values derived from 
each preparation samples to a one way Anova.  
 
2.2.8  Statistical Analysis 
Data from at least three independent experiments were expressed as mean values (+ standard 
error of the mean (SEM)). Data were statistically analysed using one way ANOVA, followed 
by Bonferroni posttests. Results with p < 0.05 were considered as significant. Analysis was 
conducted with Graph Pad Prism software 5 (GraphPad software, La Jolla, USA). 
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3.  Results  
Endocannabinoid regulation in different OHSC models of neuronal damage 
3.1  Perforant pathway transection and neuronal damage  
After  div  6,  rat  OHSC  were  lesioned  by  following  the  sulcus  between  the  EC  and  the 
hippocampal formation to secure that all projecting fibers of the EC were disconnected.  PPT 
is an indirect dendritic lesion, as the projecting axonal fibers were mechanically transsected 
without direct dendritic damage. The determination of neuronal cell death by counting the 
numbers of propidium iodide (PI) positive nuclei, revealed very few PI positive nuclei in the 
EC, the DG and the CA1 region. There was no significant change in the number of PI positive 
nuclei or IB4 positive microglia in investigated regions (EC, DG, CA1) at all time-points 
assessed (p > 0.05). No difference was found between controls and PPT slices (p > 0.05, 
n = 3).  
 
 
 
 
 
 
 
72 h after PPT, neuronal damage was hardly observed. Microglia were not significantly enhanced in 
the EC, DG and CA1 region in OHSC. 
  EC CTR 
PI         IB4 
EC PPT 
PI        IB4 
DG CTR 
PI        IB4 
DG PPT 
PI        IB4 
CA1 CTR 
PI        IB4 
CA1 PPT 
PI        IB4 
0 hpl  0.0  16  0.0  22  0.0  6  0.3  19  0.0  11  0.0  14 
1 hpl  0.0  19  0.3  26  0.3  17  0.7  23  0.0  14  0.3  11 
6 hpl  0.0  32  0.0  23  0.3  9  0.0  15  0.0  10  0.0  16 
12 hpl  0.0  25  0.0  17  0.3  18  1.7  24  0.0  8  0.0  12 
24 hpl  1.7  10  1.3  26  0.7  15  1.7  28  0.0  17  0.3  13 
48 hpl  1.7  24  1.7  33  1.0  16  1.3  25  0.7  18  0.7  15 
72 hpl  0.0  28  0.0  18  0.0  18  2.0  30  0.0  15  1.0  17 
Figure 3.1   Neuronal damage in PPT 45 
 
3.2  Endocannabinoid regulation after neuronal damage in the hippocampal 
formation 
The  different  regions  were  pooled  by  three  OHSC  to  obtain  a  net  tissue  weight  of 
approximately 1 mg per tissue. The data obtained by investigating the eCB levels after PPT 
and excitotoxic (10 and 50 µM NMDA) damage at different time points up to 72 hpl are 
shown. 
 
3.2.1  Endocannabinoid measurement 
The eCB levels of non lesioned controls (CTR) were set to 100 % and the PPT data was 
expressed in relation to their time controls, respectively. The actin content of each sample was 
examined to control for the collected amount of tissue.  
 
3.2.2  Endocannabinoid levels after PPT 
Axonal dissection/ dendritic denervation as induced by PPT, led to a site-specific intrinsic up-
regulation of AEA, PEA, OEA and 2-AG levels in the DG. Under control conditions the 
following absolute values for NEA and 2-AG were found in the investigated areas: AEA: EC, 
0.01 ng/ml; DG, 0.01 ng/ml; CA1, 0,02 ng/ml; PEA: EC, 1.00 ng/ml; DG, 1.40 ng/ml; CA1, 
1.00 ng/ml; OEA: EC, 0.50 ng/ml, DG, 0.50 ng/ml, CA1, 1.00 ng/ml, 2-AG: EC, 6.71 ng/ml; 
DG, 5.45 ng/ml; CA1, 6.06 ng/ml respectively.  
Entorhinal Cortex: In the EC region, no significant changes of the measured endocannabinoid 
levels were observed after PPT. Values are given in Tab 3.1 and shown in Fig. 3.2A. AEA 
levels in the EC remained at control levels. Only at 1 hpl a non significant elevation to 139 % 
was observed. At all time points investigated, no significant changes were detected for PEA, 
OEA or for 2-AG levels in the EC (p > 0.05).  46 
 
Dentate  Gyrus:  Values  are  given  in  Tab.  3.1.  In  the  DG,  AEA  levels  did  not  differ 
significantly from controls  up to  12 hpl.  At 24 hpl, mean AEA levels  were significantly 
increased compared to controls (24 hpl, 261 %; p < 0.001). Thereafter, AEA levels declined 
and were below the respective time control at 72 hpl (Fig. 3.2B). PEA levels in the DG did 
not differ significantly from controls up to 6 hpl. At 12 hpl, the PEA levels were elevated 
(12 hpl, 193 %, p < 0.05) and reached the maximum at 24 hpl (24 hpl, 352 %, p < 0.001). 
PEA  levels  then  declined  and  were  found  to  be  reduced  at  72  hpl  without  reaching  the 
significant threshold. OEA levels after PPT in the DG were comparable to control levels up to 
12 hpl. At 24 hpl, OEA levels were maximal elevated (24 hpl 299 %; p < 0.001). Thereafter, 
OEA levels declined and were lowered at 48 hpl and 72 hpl compared to the respective time 
controls (Fig. 3.2B). 2-AG levels did not differ significantly from controls up to 12 hpl in the 
DG.  At  24  hpl  mean  2-AG  levels  were  significantly  increased  compared  to  controls 
(Fig. 3.2B, 24 hpl, 172.20 %; p < 0.05). Thereafter, 2-AG levels declined to control levels. 
Cornu ammonis 1 In the CA1 region, no significant changes were observed in AEA levels 
(Fig.3.2C). PEA levels remained close to the control levels until 12 hpl. At 24 hpl (24 hpl, 
70 %; p> 0.05), PEA levels were below control levels reaching the significant threshold at 
48 hpl (48 hpl, 38 %; p < 0.05). OEA levels in the CA1 region were comparable to the control 
levels up to 24 hpl. At 48 hpl the OEA levels decreased significantly compared to the control 
levels (48 hpl, 44 %; p < 0.05; Fig. 3.2C). No significant changes were observed in 2-AG 
levels in the CA1 region. 
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Table 3.1  Endocannabinoid values after PPT 
 
 
EC  AEA (%)  PEA (%)  OEA (%)  2-AG (%) 
0 hpl  115; p>0.05  116; p>0.05  106; p>0.05  122; p>0.05 
1 hpl  139; p>0.05  160; p>0.05  157; p>0.05  118; p>0.05 
6 hpl  74; p>0.05  96; p>0.05  86; p>0.05  94; p>0.05 
12 hpl  121; p>0.05  143; p>0.05  130; p>0.05  119; p>0.05 
24 hpl  112; p>0.05  111; p>0.05  121; p>0.05  134; p>0.05 
48 hpl  82; p>0.05  66; p>0.05  75; p>0.05  87; p>0.05 
72 hpl  79; p>0.05  85; p>0.05  99; p>0.05  91; p>0.05 
DG  AEA (%)  PEA (%)  OEA (%)  2-AG (%) 
0 hpl  113; p>0.05  111; p>0.05  101; p>0.05  79; p>0.05 
1 hpl  122; p>0.05  132; p>0.05  129; p>0.05  107; p>0.05 
6 hpl  90; p>0.05  124; p>0.05  131; p>0.05  114; p>0.05 
12 hpl  142; p>0.05  193; p<0.05  143; p>0.05  120; p>0.05 
24 hpl  261; p<0.001  352; p<0.001  299; p<0.001  172; p<0.01 
48 hpl  79; p>0.05  56; p>0.05  61; p>0.05  98; p>0.05 
72 hpl  82; p>0.05  76; p>0.05  81; p>0.05  101; p>0.05 
CA1  AEA (%)  PEA (%)  OEA (%)  2-AG (%) 
0 hpl  114; p>0.05  92; p>0.05  84; p>0.05  89; p>0.05 
1 hpl  107; p>0.05  119; p>0.05  112; p>0.05  82; p>0.05 
6 hpl  113; p>0.05  111; p>0.05  132; p>0.05  93; p>0.05 
12 hpl  66; p>0.05  76; p>0.05  77; p>0.05  77; p>0.05 
24 hpl  90; p>0.05  70; p>0.001  64; p>0.015  74; p>0.05 
48 hpl  59; p>0.05  38; p<0.05  44; p<0.05  80; p>0.05 
72 hpl  106; p>0.05  92; p>0.05  98; p>0.05  138; p>0.05 48 
 
ECB levels (grey cycles) were related to control conditions (CTR, black cycles) of each time-point 
respectively and CTR was set to 100 %. In the EC, no alteration of the eCB levels was observed. In 
the DG, all investigated eCB were significantly increased after 24 hpl. PEA was also 12 hpl increased 
compared to the respective control. In the CA1, AEA and 2-AG showed no changes after PPT. PEA 
and OEA decreased after 48 hpl (n = 4, *p < 0.05, **p < 0.01, ***p < 0.001). 
 
3.2.3  Endocannabinoid levels after excitotoxicity  
ECB levels are regulated in a site specific and time dependent manner after excitotoxic lesion 
and PPT. The eCB levels of non lesioned controls (CTR) were set to 100 %. The NMDA and 
PPT data were expressed in relation to their time controls, respectively. Exciotoxic NMDA 
lesion led to an intrinsic up-regulation of eCB levels in the EC, DG and in the CA1 region 
after low and high excitotoxic lesion (NMDA, 10 µM and 50 µM, Fig. 3.3). 
Entorhinal cortex: AEA levels were enhanced 24 hpl in the EC after low and high NMDA 
concentrations shown in Tab. 3.2 and Fig 3.3A. At 24 hpl, high NMDA application AEA 
levels were significantly enhanced compared to low NMDA treatment (10 µM: 24 hpl, 579 % 
vs.  50  µM:  24  hpl,  1298  %;  p  <  0.05).  PEA  levels  were  not  increased  at  low  NMDA 
concentration, whereas after high NMDA supplementation at 24 hpl, an up-regulation was 
observed in the EC region. At 24 hpl, high NMDA application PEA levels were significantly 
enhanced compared to low NMDA treatment (10 µM: 24 hpl, 557 % vs. 50 µM: 24 hpl, 
1274 %; p < 0.05). OEA levels were enhanced after 24 hpl in the EC after high NMDA 
application.  At  24  hpl,  high  NMDA  application  OEA  levels  were  significantly  enhanced 
compared to low NMDA treatment (10 µM: 24 hpl, 635 % vs. 50 µM: 24 hpl, 1355 %; p < 
0.05). 2-AG levels remained at control levels in the EC after 10 µM NMDA and after high 
NMDA treatment. No differences were seen between low or high NMDA application.  
Figure 3.2  Endocannabinoid (eCB) levels after PPT in EC, DG and the CA1 region 
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Dentate  gyrus:  AEA  levels  in  the  DG  were  significantly  up-regulated  at  all  time  points 
measured after low NMDA application. At high NMDA concentration, the measurements 
became significant at 24 hpl. High NMDA application enhanced AEA levels significantly 
24 hpl compared to low NMDA treatment (10 µM: 24 hpl, 340 % vs. 50 µM: 24 hpl, 653 %; 
p < 0.05). PEA levels in the DG were significantly up-regulated at all time points measured 
independently from the used NMDA concentration. 24 and 72 hpl high NMDA application 
enhanced PEA levels significantly compared to low NMDA treatment (10 µM: 24 hpl, 330 % 
vs. 50 µM: 24 hpl, 705 %, p < 0.05 and 10 µM: 72 hpl, 640 % vs. 50 µM: 72 hpl, 1008 %, 
p < 0.05). OEA levels in the DG were significantly up-regulated at all time points measured, 
independent from the used NMDA concentration. 24 and 72 hpl, high NMDA application 
enhanced OEA levels significantly compared to low NMDA treatment (10 µM: 24 hpl, 356 % 
vs. 50 µM: 24 hpl, 738 %, p< 0.001 and 10 µM: 72 hpl, 560 % vs. 50 µM: 72 hpl, 804 %, 
p < 0.001). 2-AG levels In the DG were enhanced 72 hpl by low NMDA (308 %; p < 0.001, 
vs. CTR) but not at 4 hpl and 24 hpl. 50 µM of NMDA increased 2-AG levels from 24 hpl on 
(Fig. 3.3A) 
Cornu ammonis 1: AEA levels were enhanced 24 and 72 hpl in the CA1 region after low 
NMDA  concentrations  and  24  hpl  after  high  NMDA  treatment.  24  hpl,  high  NMDA 
application enhanced AEA levels significantly compared to low NMDA treatment (10 µM: 
24 hpl, 890 % vs. 50 µM: 24 hpl, 1628 %; p < 0.001). PEA levels were enhanced 24 and 72 
hpl  in  the  CA1  region  after  low  and  high  NMDA  concentrations.  24  hpl,  high  NMDA 
application enhanced PEA levels significantly compared to low NMDA treatment (10 µM: 24 
hpl, 902 % vs. 50 µM: 24 hpl, 1732 %; p < 0.001). OEA levels were enhanced 24 and 72 hpl 
in the CA1 region after low NMDA concentrations and 24 hpl after high NMDA treatment. 
24 hpl, high NMDA application enhanced OEA levels significantly compared to low NMDA 
treatment (10 µM: 24 hpl, 937 % vs. 50 µM: 24 hpl, 1711 %; p < 0.001). 2-AG levels of the 50 
 
CA1  region  treated  with  10  µM  NMDA  showed  a  significant  increase  72  hpl  (364  %; 
p < 0.001, vs. CTR). After treatment with 50 µM NMDA, 2-AG was enhanced after 24 and 
72 hpl. 24 hpl, high NMDA application enhanced AEA levels significantly compared to low 
NMDA treatment (10 µM: 24 hpl, 185 % vs. 50 µM: 24 hpl, 290 %; p < 0.05). 
 
Table 3.2  Endocannabinoid values after excitotoxic lesion 
 
EC  AEA (%) 
10 µM      50 µM 
PEA (%) 
10 µM      50 µM 
OEA (%) 
10 µM      50 µM 
2-AG (%) 
10 µM      50 µM 
4 hpl  333; 
p>0.05 
142; 
p>0.05 
500; 
p>0.05 
309; 
p>0.05 
521; 
p>0.05 
296; 
p>0.05 
94; 
p>0.05 
63; 
p>0.05 
24 hpl  579; 
p<0.05 
1298; 
p<0.001 
557; 
p>0.05 
1274; 
p<0.001 
635; 
p>0.05 
1355; 
p<0.001 
68; 
p>0.05 
87; 
p>0.05 
72 hpl  148; 
p>0.05 
129; 
p>0.05 
379; 
p>0.05 
336; 
p>0.05 
262; 
p>0.05 
255; 
p>0.05 
114; 
p>0.05 
103; 
p>0.05 
DG  AEA (%) 
10 µM      50 µM 
PEA (%) 
10 µM      50 µM 
OEA (%) 
10 µM      50 µM 
2-AG (%) 
10 µM      50 µM 
4 hpl  279; 
p<0.01 
234; 
p>0.05 
397; 
p<0.01 
399; 
p<0.01 
453; 
p<0.001 
433; 
p<0.001 
140;  
p> 0.05 
124; 
p>0.05;  
24 hpl  340; 
p<0.001 
653; 
p<0.001 
330; 
p<0.05 
705; 
p<0.001 
356; 
p<0.05 
738; 
p<0.001 
147; 
p>0.05 
198; 
p<0.01; 
72 hpl  375; 
p<0.001 
462, 
p<0.001 
640; 
p<0.001 
1008; 
p<0.001 
560; 
p<0.001 
804; 
p<0.001 
308; 
p<0.001 
324; 
p<0.001, 
CA1  AEA (%) 
10 µM      50 µM 
PEA (%) 
10 µM      50 µM 
OEA (%) 
10 µM      50 µM 
2-AG (%) 
10 µM      50 µM 
4 hpl  245; 
p>0.05 
164; 
p>0.05 
396; 
p>0.05 
341; 
p>0.05 
495; 
p>0.05 
382; 
p>0.05 
63; 
p>0.05 
114; 
p>0.05 
24 hpl  890; 
p<0.001 
1628; 
p<0.001 
902; 
p<0.001 
1732; 
p<0.001 
937; 
p<0.001 
1711; 
p<0.001 
185; 
p>0.05 
290; 
p<0.001 
72 hpl  502; 
p<0.01 
414; 
p>0.05 
635; 
p<0.01 
545; 
p<0.05 
592; 
p<0.05 
487; 
p>0.05 
364; 
p<0.001 
307; 
p<0.001 51 
 
 
Figure 3.3  Endocannabinoid levels after excitotoxicity 
Endocannabinoid levels after excitotoxicity in EC, DG and the CA1 region. 10 µM of NMDA (open 
cycles) and 50 µM of NMDA (grey cycles) were related to control conditions (CTR, black cycles) of 
each time-point, respectively and CTR was set to 100 %. In the EC, AEA, PEA and OEA levels were 
increased 24 hpl and decreased at 72 hpl back to control levels. 2-AG did not show any alteration in 
comparison to the respective CTR in the EC. In the DG, all investigated eCB were significantly 
increased after 10 µM of NMDA treatment and were even further increased after 50 µM NMDA. In 
the CA1, AEA, PEA and OEA showed a dose dependent peak to NMDA treatment 24 hpl. 2-AG 
increased 24 hpl at both concentrations of NMDA and remained up-regulated after 72 hpl. (n = 3, 
*/
+p < 0.05, **/
++p < 0.01, ***/
+++p < 0.001). 
 
3.3  Differential regulation of enzymes and receptors of NEA after PPT 
The  site-specific  and  time-dependent  changes  in  enzymes,  namely  NAPE-PLD,  FAAH, 
NAAA as well as receptors CB1 and PPARα were analysed by Western blot. The specificity 
of the used antibodies was tested by means of preabsorption. The CB1 antibody showed no 
signal in CB1
-/- animals. For densitometric analysis, the PPT data was expressed relative to 
their time-controls respectively and the control levels were set to 100 %.  52 
 
3.3.1  CB1 and PPARα receptor regulation after PPT 
Entorhinal Cortex: After PPT, CB1 protein (0 hpl, 86 %; 1 hpl, 94 %; 6 hpl, 129 %; 12 hpl, 
92 %; 24h, 101 %; 48 hpl, 108 %; 72 hpl, 132 %; p > 0.05;  Fig. 3.4) was significantly 
increased 1 hpl (129 %; p < 0.05) and 72 hpl (132 %; p < 0.05) in the EC only. PPARα (0 hpl, 
83 %; 1 hpl, 105 %; 6 hpl, 93 %; 12 hpl, 112 %; 24h, 76 %; 48 hpl, 112 %; 72 hpl, 111 %; 
p > 0.05; Fig. 3.4) showed no alteration in PPT compared to the respective time control.  
Dentate Gyrus: The protein amount of CB1 did not differ from the time control (0 hpl, 119 %; 
1 hpl, 101 %; 6 hpl, 77 %; 12 hpl, 107 %; 24h, 123 %; 48 hpl, 105 %; 72 hpl, 109 %; 
p > 0.05, Fig. 3.4). The PPARα protein amount did not change in comparison to the time 
controls (1 hpl 102 %, 6 hpl 107 %, 12 hpl 114 %, 24h 87 %, 48 hpl 107 %, 72 hpl 92 %, 
p > 0.05, Fig. 3.4).  
 
 
 
 
 
 
 
 
 
                                                                                                     
                                      
                    
The amount of CB1 protein was significantly elevated 6 hpl whereas PPARα was not altered.  
Figure 3.4  CB1 and PPARα receptor regulation after PPT 53 
 
Cornu ammonis 1: In PPT, CB1 (0 hpl, 93 %; 1 hpl, 106 %; 6 hpl, 87 %; 12 hpl, 94 %; 24h, 
99 %; 48 hpl, 126 %; 72 hpl, 82 %; p > 0.05; Fig. 3.4) as well as PPARα (0 hpl, 86 %; 1 hpl, 
97 %; 6 hpl, 135 %; 12 hpl, 110 %; 24h, 97 %; 48 hpl, 124 %; 72 hpl, 69 %; p > 0.05; 
Fig. 3.4) were not altered after PPT in CA1 as compared to the respective time controls. 
 
3.3.2  Enzymatic regulation of NEA after PPT 
Entorhinal Cortex: No change in NAPE-PLD was detectable after axonal damage in the EC 
(0 hpl, 98 %; 1 hpl, 114 %; 6 hpl, 105 %; 12 hpl, 114 %; 24h, 102 %; 48 hpl, 111 %; 72 hpl, 
119 %; p > 0.05; Fig. 3.5). Neither FAAH (0 hpl, 83 %; 1 hpl, 115 %; 6 hpl, 104 %; 12 hpl, 
98 %; 24h, 88 %; 48 hpl, 97 %; 72 hpl, 90 %; p > 0.05; Fig. 3.5) nor NAAA (0 hpl, 88 %; 
1 hpl, 89 %; 6 hpl, 79 %; 12 hpl, 98 %; 24h, 101 %; 48 hpl, 100 %; 72 hpl, 105 %; p > 0.05; 
Fig. 3.5) were significantly changed.  
Dentate Gyrus: An increase of NAPE-PLD protein amount was observed in DG from 1 hpl to 
6 hpl (0 hpl, 97 %; p>0.05; 1 hpl, 140 %; 6 hpl, 133 %; p < 0.05; Fig. 3.5). Thereafter, NAPE-
PLD protein decreased to control levels (12 hpl, 133 %; 24h, 118 %; 48 hpl, 117 %; 72 hpl, 
99 %; p > 0.05). The FAAH protein amount remained close to control levels up to 24 hpl 
(1 hpl, 110 %; 6 hpl, 108 %; 12 hpl, 106 %; 24 hpl, 111 %; p > 0.05). At 48 hpl, (120 %; 
p < 0.05) a significant peak of FAAH was observed that was not visible anymore at 72 hpl 
(113 %; p > 0.05; Fig. 3.5). No change in the NAAA enzyme was detectable after dendritic 
denervation in the DG (1 hpl 101 %, 6 hpl 98 %, 12 hpl 95 %, 24h 128 %, 48 hpl 105 %, 
72 hpl 111 %, p > 0.05).  
Cornu ammonis 1: In the CA1 region, no alterations in NAPE-PLD were detected (0 hpl, 
89 %; 1 hpl, 100 %; 6 hpl, 112 %; 12 hpl, 109 %; 24h, 86 %; 48 hpl, 100 %; 72 hpl, 86 %; 
p > 0.05; Fig. 3.5). FAAH (0 hpl, 111 %; 1 hpl, 100 %; 6 hpl, 97 %; 12 hpl, 114 %; 24h, 54 
 
94 %; 48 hpl, 87 %; 72 hpl, 102 %; p> 0.05; Fig. 3.5) and NAAA (0 hpl, 111 %; 1 hpl, 
105 %; 6 hpl, 107 %; 12 hpl, 102 %; 24h, 99 %; 48 hpl, 106 %; 72 hpl, 81 %; p > 0.05) 
remained unchanged after PPT.  
 
 
Figure 3.5   Enzymatic regulation of NEA after PPT 
Relative amount of NAPE-PLD, FAAH and NAAA after PPT compared to respective time controls 
(CTR) set to 100 %. NAPE-PLD, FAAH and NAAA remained constant after PPT in EC. In DG, 
NAPE-PLD was increased 1 and 6 hpl. FAAH showed elevated levels 48 hpl, whereas NAAA did not 
show any alteration after PPT. In CA1, NAPE-PLD, FAAH and NAAA remained unchanged after 
PPT. (n = 4, *p < 0.05) 
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3.4  Enzymatic and transcriptional regulation of 2-AG after PPT 
Western Blot analysis and semi-quantitative real time PCR (rtPCR) were used to investigate 
the intrinsic regulation of the synthesising (DAGL) and the hydrolyzing (MAGL) enzymes of 
2-AG in the different regions over time.  
 
3.4.1  Enzymatic regulation of 2-AG after PPT 
Entorhinal cortex: No changes of DAGL and MAGL protein were observed in the EC region 
after PPT compared to the time control OHSC (DAGL: 0 hpl, 101 %; 6 hpl, 85 %; 12 hpl, 
79 %; 24 hpl, 119 %; 48 hpl, 101 %; p > 0.05; MAGL: 0 hpl, 105 %; 6 hpl, 112 %; 12 hpl, 
103 %; 24 hpl, 99 %; 48 hpl, 98 %; p > 0.05, Fig. 3.6).  
Dentate gyrus: DAGL protein was decreased 24 hpl significantly (Fig. 3.6, 24 hpl, 66 %; 
p < 0.05) related to the respective controls (0 hpl, 102 %; 6 hpl, 101 %; 12 hpl, 107 %, 48 hpl, 
84 %; p > 0.05). MAGL expression did not show significant changes (MAGL: 0 hpl, 104 %; 
6 hpl, 120 %; 12 hpl, 123 %; 24 hpl, 115 %; 48 hpl, 95 %; p > 0.05).  
Cornu ammonis 1: In the CA1 region no significant changes were observed in DAGL or 
MAGL protein expression (DAGL: 0 hpl, 92 %; 6 hpl, 114 %; 12 hpl, 88 %; 24 hpl, 97 %; 
48 hpl, 99 %; p > 0.05, MAGL: 0 hpl, 110 %; 6 hpl, 109 %; 12 hpl, 117 %; 24 hpl, 130 %; 
48 hpl, 103 %; p > 0.05, Fig. 3.6).  56 
 
DAGL and MAGL protein (open cycles) regulation after PPT in the entorhinal cortex (EC) and the 
hippocampus (DG, CA1) normalized to time controls (closed cycles). DAGL was decreased 24 hpl in 
the DG. After PPT no further changes could be observed (n = 3, *p < 0.05). 
 
 
3.4.2  Transcriptional regulation of DAGL and MAGL after PPT  
Entorhinal cortex: In the EC region, no changes of both enzymes were observed after PPT. 
DAGL  and  MAGL  expression  were  not  significantly  increased  compared  to  the  control 
OHSC (DAGL: 6 hpl, 55 %; 12 hpl, 87 %; 24 hpl, 70 %; 48 hpl, 107 %; p > 0.05; MAGL: 
6 hpl, 68 %; 12 hpl, 103 %; 24 hpl, 112 %; 48 hpl, 137 %; p > 0.05, Fig. 3.7).  
Dentate gyrus: In the DG, DAGL expression was significantly enhanced 24 hours after PPT 
(24 hpl, 175 %; p < 0.05, Fig. 3.7) related to the respective controls (6 hpl, 132 %; 12 hpl, 108 
%, 48 hpl, 65 %; p > 0.05). MAGL expression did not show significant changes (MAGL: 
6 hpl, 78 %; 12 hpl, 76 %; 24 hpl, 76 %; 48 hpl, 113 %; p > 0.05).  
Figure 3.6  Enzymatic regulation of 2-AG after PPT 57 
 
Cornu ammonis 1: In the CA1 region, no significant changes were observed in DAGL or 
MAGL expression (DAGL: 6 hpl, 77 %; 12 hpl, 92 %; 24 hpl, 92 %; 48 hpl, 77 %; p > 0.05, 
MAGL: 6 hpl, 157 %; 12 hpl, 83 %; 24 hpl, 111 %; 48 hpl, 123 %; p > 0.05, Fig. 3.7).  
 
 
Figure 3.7  DAGL and MAGL transcription after PPT 
DAGL and MAGL mRNA regulation after PPT in the entorhinal cortex and the hippocampus. DAGL 
was increased 24 hpl in the DG (n = 3, *p < 0.05).  
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3.5  Immunohistochemical analysis of eCB regulating enzymes in OHSC 
3.5.1.  CB1 and PPARα after PPT in OHSC 
A strong CB1 immunosignal was detected in the inner and outer molecular layer of the DG. 
CB1 was present in some morphologically characterised inter-neurons of the hilus. Whereas 
IB4 positive microglia displayed a positive immunosignal for CB1, this reaction was weak 
when  GFAP  immunoreactive  astrocytes  were  examined.  PPARα  was  found  in  NeuN 
immunoreactive neurons, IB4 positve microglia and GFAP positive astrocytes. PPARα was 
localised  in  vesicular  structures  close  to  the  cell  nucleus,  apparently  reflecting  the  Golgi 
apperatus throughout the entire OHSC. 
 
3.5.2  NAPE-PLD, FAAH, and NAAA after PPT in OHSC 
Localisations of NAPE-PLD, FAAH, NAAA, CB1 and PPARα immunoreactions (IR) were 
investigated  by  immunohistochemical  staining  with  NeuN,  GFAP  and  IB4  in  sections 
obtained from OHSC at 24 hpl shown in Fig 3.8. NAPE-PLD immunoreaction was found to 
be co-localised with NeuN positive neurons and a subset of IB4 positive microglia. GFAP 
positive  astrocytes  did  not  show  a  NAPE-PLD  immunoreaction.  FAAH  immunoreactions 
showed a robust cytoplasmic distribution in neuronal cells. Neither microglial cells nor GFAP 
positive  astrocytes  exhibited  a  detectable  amount  of  FAAH.  Co-localszation  of  NAAA 
immunoreaction  with  NeuN  positive  neurons  was  observed,  mainly  in  the  perikarya.  In 
addition, some nuclei showed positive immunoreactions for NAAA. There was no overlap of 
NAAA immunoreaction with IB4 or GFAP positive cells. 
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Immunocytochemical analysis of NAPE-PLD, FAAH, NAAA, CB1 and PPARα in the dentate gyrus 
of OHSC 24 hpl. Left column: DG in overview after DAB staining. Middle column; Triple staining of 
eCB system related proteins with NeuN and IB4. Right column; Triple staining of OHSC with eCB 
system related proteins in combination with NeuN and GFAP. The granular cell layer of the DG and 
interneurons in the hilus region showed a strong immunoreaction for NAPE-PLD. No overlap was 
observed with GFAP or IB4. The granular cell layer of the DG and especially interneurons in the hilus 
region were strongly immunoreactive for FAAH. No overlap was observed with GFAP or IB4. Please 
note the similarity of staining pattern of NAPE-PLD and FAAH immunoreactions. NAAA was found 
in perikarya and nuclei of neurons. In addition to the granular cell layer of the DG and hilar neurons, 
the  CA3  region  was  strongly  labeled.  Astrocytes  and  microglia  seem  to  be  not  NAAA 
immunoreactive.  The  entire  molecular  layer  of  the  dentate  gyrus  showed  a  positive  CB1 
immunoreaction.  CB1  was  present  in  microglia  and  to  a  lesser  extent  in  astrocytes.  PPARα  was 
observed  in  perikarya  and  nuclei  of  neurons.  Microglia  and  astrocytes  showed  a  positive 
immunoreaction for PPARα (n = 3, bars: left column = 100 µm, middle and right columns = 50 µm). 
 
 
3.5.3  DAGL and MAGL in excitotoxically and dendritic lesioned OHSC 
DAGL protein was found in the cytoplasm of NeuN positive cells. Also, co-localisation of 
DAGL with GFAP positive astrocytes was observed but no immunoreaction was seen in IB4 
positive cells (Fig.3.9). 
No changes  could  be found in  PPT OHSC until  12 hpl.  The DAGL  IR  remained in  the 
cytoplasm of neurons and astrocytes. 24 hpl reorganization of DAGL IR was observed, the 
tight organisation of the granular cell layer dispersed and DAGL IR was found in the outer 
third  of  the  granular  layer  but  vanished  in  the  inner  half  of  the  granular  layer.  MAGL 
immunoreactions showed only a weak punctual distribution in NEUN positive cells. GFAP 
positive  astrocytes  expressed  strong  co-localisation  with  the  MAGL  protein.  Microglia 
displayed only weak MAGL IR in OHSC (Fig.3.9). Over time, microglia did not show a 
change of MAGL expression as expected after cell culture experiments. Some co-localisation 
Figure 3.8  Immunocytochemical analysis of OHSC  61 
 
of IB4 and MAGL could be due to phagocytosis of cell vesicles by microglia. At 24 hpl 
MAGL  IR  was  less  expressed  in  GFAP  positive  cells.  No  other  changes  in  cellular 
distribution were observed over time. 
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DAGL and MAGL immunoreaction in OHSC 24 h after PPT. DAGL was co-localised with GFAP 
positive cells IB4 positive microglia were not DAGL IR. After PPT, a reorganisation of DAGL IR was 
seen. The outer half of the granular cell layer kept immunoreactive whereas the inner half of the 
granular cell layer was not DAGL IR 24 hpl. GFAP positive cells expressed strong co-localisation 
with the MAGL protein. Microglial cells displayed little MAGL IR in OHSC. 24 hpl, MAGL protein 
was less expressed in astrocytes. No other alteration in cellular distribution was seen. (bar = 50 µm) 
 
3.6  Immunohistochemical analysis of eCB regulating enzymes in primary cell 
culture 
Cell cultures often demonstrate different expression patterns and activation states as in tissue 
culture  or  in  vivo.  To  analyse  each  cell  type  precisely,  primary  neurons,  microglia  and 
astrocyte cultures were investigated whether they express receptors and enzymes of the eCB.  
 
3.6.1  Cellular distribution of CB1 and PPARα in primary rat neurons, microglia and 
astrocytes  
Neurons showed a strong CB1 immunoreaction in perikarya, primary and secondary neuronal 
processes and spines. Primary microglia culture and primary astrocytes demonstrated a clear 
CB1  immunoreaction  at  the  membrane  and  processes,  although  the  immunoreaction  in 
astrocytes  was  very  weak.  PPARα  immunoreaction  was  detectable  in  primary  neurons, 
microglia and astrocytes. In neurons, PPARα was scattered over the entire perikarya, whereas 
in glial cells, PPARα was found close to the nuclei respectively. 
 
Figure 3.9   Immunocytochemical analysis of MAGL and DAGL in OHSC 63 
 
3.6.2  Cellular distribution of NAPE-PLD, FAAH and NAAA in primary rat neurons, 
microglia and astrocytes 
In isolated primary neuronal cell cultures, NAPE-PLD immunoreaction was observed within 
neuronal perikarya and processes (Fig. 3.10).  
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Immunocytochemical analysis of NAPE-PLD, FAAH, NAAA, CB1 and PPARα in primary neuronal 
(left column), microglia (middle column) and astrocyte (left column) cell cultures. In neurons, NAPE-
PLD  was  distributed  in  the  perikarya  but  not  in  neuronal  processes.  In  microglia,  NAPE-PLD 
immunoreactions were detectable in small vesicles closely located to the nucleus. NAPE-PLD was not 
found in protoplasmic astrocytes, whereas fibrillary astrocytes showed an immunosignal comparable 
to microglia. The immunosignal for FAAH in primary neurons was localised in the cell bodies as well 
as in the primary branches of the neurites. In microglia and astrocytes, FAAH was localised within the 
nucleus respectively. In fibrillary astrocytes a FAAH immunoreaction was additionally observed in 
vesicles. NAAA was clearly found in neurons but was barely found in microglia and astrocytes. In 
microglia NAAA showed a vesicular staining pattern close to the nucleus. Protoplasmic astrocytes 
were  immunoreactive  for  NAAA,  whereas  fibrillary  astrocytes  did  not  show  any  NAAA 
immunosignal.  A  robust  CB1  immunoreaction  was  found  in  neurons.  To  a  lower  extent,  CB1 
immunosignals were detectable in microglia and astrocytes. Primary neurons showed a strong PPARα 
immunoreaction in their Perikarya and nuclei. Microglia and astrocytes were positive for PPARα 
immunoreaction in a vesicular pattern. (n = 3, bar = 20 µm) 
 
 
Similar to OHSC, NAPE-PLD was found close to the nuclei in microglial cells. In primary 
astrocyte  culture  fibrillary  astrocytes  displayed  a  weak,  protoplasmic  astrocytes  a  robust 
NAPE-PLD immunoreaction. Primary neurons,  microglia and  astrocytes showed a FAAH 
immunoreaction that was localised close to the nuclei respectively (Fig. 3.10).  In addition, 
nuclear labeling was observed in microglia and astrocytes. Isolated primary neurons showed a 
NAAA immunoreaction that was found to be distributed in the perikarya and the secondary 
branches. Microglia was labeled with the NAAA antibody close to the nucleus. Fibrillary 
astrocytes displayed NAAA immunoreactions within their cell bodies and to a minor extent in 
their processes (Fig. 3.10).  
 
 
Figure 3.10  Immunocytochemical analysis of primary cell cultures 65 
 
3.6.3  Cellular distribution of DAGL and MAGL in primary rat neurons, microglia and 
astrocytes  
In isolated primary neuronal cultures DAGL IR were observed within neuronal perikarya and 
processes.  The  double  staining  of  DAGL  and  VGUT1  showed  punctual  co-localisation 
(Fig. 3.11). MAGL IR was not observed to be co-localised with VGLUT1 in primary neuronal 
cell  culture.  In  primary  microglia  cultures  DAGL  IR  were  located  in  the  cell  body  that 
became more intense after LPS treatment (Fig. 3.11). DAGL was differentially expressed in 
astrocyte subtypes whereas fibrillary astrocytes showed a weak DAGL IR, especially after 
LPS  treatment.  Protoplasmic  astrocytes  displayed  punctual  immunoreactions  spread 
throughout  the  cell  body  under  both,  control  and  LPS  treated  conditions.  In  IB4  positive 
microglia, MAGL was found in the cytoplasm and at the cell borders. Interestingly MAGL IR 
disappeared  after  LPS  treatment.  Fibrillary  astrocytes  displayed  MAGL  immunoreactions 
within their cell bodies. In LPS treated cells, MAGL IR was seen in the cell bodies and to a 
minor extent in their processes. The immunoreaction of MAGL in protoplasmic astrocytes 
was weak, no alteration was observed between the control and the LPS treated condition (Fig. 
3.11).  66 
 
Immunocytochemical analysis of DAGL and MAGL in primary neuronal (left column), microglia, 
(middle column) and astrocyte (left columns) cell cultures. In neurons, DAGL was distributed in the 
perikarya  and  in  neuronal  processes.  VGLUT1  was  co-localised  with  DAGL  suggesting  a  close 
surveillance  of  glutamate  by  DAGL.  (white  arrow).  MAGL  was  distributed  in  primary  neuronal 
cultures but displayed no overlap with VGLUT1. Microglia were labeled with DAGL in the cell body, 
after LPS treatment DAGL expression was stronger than in controls. However, MAGL expression in 
microglia was clearly visualised under control condition at the outer edges of the cells but disappeared 
in the LPS treated condition. DAGL IR was not found in fibrillary astrocytes under control condition, 
but  little  DAGL  IR  was  seen  after  LPS  treatment  in  fibrillary  astrocytes,  whereas  protoplasmic 
astrocytes displayed DAGL IR in control and stimulated condition visualised in droplets throughout 
the cell body. MAGL IR was stimulated in LPS conditioned fibrillary and protoplasmic astrocytes. 
Under control conditions, only some MAGL IR was found in fibrillary astrocytes (n = 3, bar = 20 µm). 
Figure 3.11  Immunocytochemical analysis of DAGL and MAGL in primary cell culture 67 
 
3.7  Neuroprotection after intrinsic 2-AG upregulation 
3.7.1  Intrinsic upregulation of 2-AG after MAGL inhibition by JZL184 in OHSC 
To  determine  the  intrinsic  regulation  of  2-AG  after  neuronal  damage,  2-AG  levels  were 
measured after MAGL inhibition. Raw values of 3 pooled OHSC (EC, DG or CA1) were 
about 3-5 ng/ml for 2-AG under control condition. The obtained 2-AG values were corrected 
for their ß-actin content and were then given in % of the respective controls. After JZL184 
(1 µM) supplementation for 4 h, 2-AG could increase up to 35-45 ng/ml in OHSC and was 
significantly elevated in all studied regions (EC, 736 %; p < 0.01; DG, 688 %; p < 0.01, CA1, 
570 %; p < 0.05, Fig.3.12).  
 
Regulation of 2-AG in EC, DG and CA1.  A 
significant increase of 2-AG levels in all three 
regions of the Hippocampus (DG and CA1) and 
the  entorhinal  cortex  (EC)  after 
supplementation  of  JZL  184  for  72  h  to  the 
culture media (n = 4).  
 
 
 
3.7.2  JZL184 protected dentate gyrus granule cells after excitotoxic lesion in OHSC 
Non-lesioned  control  OHSC  exhibited  a  good  neuronal  preservation  with  almost  no  PI 
positive neuronal nuclei. All conditions were normalised to the positive NMDA control and 
given in % (Fig. 3.13A). The application of 1 µM JZL184 did not lead to any significant 
alterations within the number of PI positive neuronal nuclei compared to the negative control 
Figure 3.12   Regulation of 2-AG after 
JZL184 regulation 68 
 
(JZL184, 0 %, p > 0.05). Treatment of OHSC with 50 µM NMDA for 4 hours at 6 div 
strongly increased the numbers of PI positive cells in the dentate gyrus (DG) granule cell 
layer (GCL) (NMDA, 156 26 PI postitive neuronal nuclei, 100 %, p < 0.001 vs. negative 
CTR) as compared to untreated OHSC. Application of 1 µM JZL184 to NMDA-lesioned 
OHSC led to a significant reduction of PI positive neuronal nuclei compared to NMDA alone 
(NMDA+1 µM JZL184, 51 %; p < 0.05 vs. NMDA, Fig.3.13A).  
 
 
MAGL  inhibition  led  to  neuroprotection  and  increased  intrinsic  2-AG  levels.  (A)  To  investigate 
wheather  2-AG  increase  is  neuroprotective,  we  increased  2-AG  levels  by  MAGL  inhibition  and 
received significantly less PI positive neurons in the DG after NMDA (50 µM) lesion and JZL 184 
(1 µM) treatment then in the NMDA control OHSC (as former research of our lab showed as well with 
2-AG  suplementation,  Kreutz,  2009).  (B)  Also  the  MAGL  knock  down  by  siRNA  reduced  the 
damaged neurons significantly.  
 
 
 
Figure 3.13  MAGL inhibition protects neuronal cell death 69 
 
3.7.3  MAGL knock down by siRNA protected NMDA lesioned OHCS  
All conditions were normalised to the positive NMDA control and given in % (Fig. 3.13B). 
Non-lesioned OHSC treated with negRNA or siRNA (negRNA, 0 % siRNA, 0 %) exhibited 
no different neuronal preservation than the control OHSC. Treatment of OHSC with 50 µM 
NMDA for 4 hours at 6 div, strongly inducted the numbers of PI positive neuronal nuclei 
(NMDA, 100 %, p < 0.001 vs. CTR) as compared to untreated CTR. Application of negRNA 
to  NMDA-lesioned  OHSC  showed  no  changes  (NMDA+negRNA,  122  %;  p  >  0.05  vs. 
NMDA), but the application of siRNA led to a significant reduction of PI positive neuronal 
nuclei compared to OHSC treated with NMDA alone (NMDA+siRNA, 33 %; p < 0.05 vs. 
NMDA, Fig. 3.13B).  
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GPR55 activation promotes neuroprotection in OHSC  
3.8  LPI protected dentate gyrus granule cells and reduced the number of 
microglia after excitotoxic lesion in OHSC  
All conditions were normalised to the positive NMDA control, 136.47 15.82 PI positive 
cells/GCL and 27.25 1.83 IB4 positive cells/GCL. Non-lesioned control OHSC exhibited a 
good neuronal preservation with almost no PI positive neuronal nuclei (CTR, 1 %) and IB4 
positive microglial cells (CTR, 13 %) Compared to CTR, the application of 1 µM LPI did not 
led to any significant alterations within the number of PI positive neuronal nuclei (LPI, 2 %, 
p > 0.05 vs. CTR, Fig. 3.14A) and IB4 positive microglial cells (LPI, 5 %, p > 0.05 vs. CTR, 
Fig. 3.14B). Treatment of OHSC with 50µM NMDA for 4 hours at 6 div strongly inducted 
the numbers of PI positive neuronal nuclei (NMDA, 100 %, p < 0.001 vs. CTR) and IB4 
positive microglial cells (NMDA, 100 %, p < 0.001 vs. CTR). Application of 1 µM LPI to 
NMDA-lesioned  OHSC  led  to  a  significant  reduction  of  PI  positive  neuronal  nuclei 
(NMDA+1 µM LPI, 56 %; p < 0.001 vs. NMDA Fig. 3.14A). Treatment of NMDA-lesioned 
OHSC with 1 µM LPI significantly reduced the number of IB4 positive microglia as compared 
to NMDA-lesioned OHSC (NMDA+1µM LPI, 62 %, p < 0.01 vs. NMDA, Fig. 3.14B).  
 
3.8.1  Concentration dependent effect of LPI on excitotoxically lesioned OHSC  
Application of 1 nM-10 µM LPI to NMDA-lesioned OHSC led to a reduction of PI positive 
neuronal nuclei, whereas 10 pM-0.1 nM LPI showed no effect as compared to OHSC treated 
with NMDA alone (NMDA+1 nM LPI, 45 %; NMDA+10 nM LPI, 32 %; NMDA+0.1 µM, 
46  %;  NMDA+10  µM  LPI,  57  %;  p  <  0.001  vs.  NMDA,  respectively;  NMDA; 
NMDA+100 pM LPI, 106 %; p > 0.05 vs. NMDA, respectively Fig. 3.14A). NMDA-lesioned 
OHSC treated with 0.1 µM-10 µM LPI, showed reduced IB4 positive microglia as compared 71 
 
to NMDA-lesioned OHSC whereas 10 pM-10 nM LPI showed no effects (NMDA+0.1 µM, 
63 %; NMDA+10 µM LPI, 60; p < 0.01 vs. NMDA, respectively., NMDA+100 pM LPI, 94 
% NMDA+1 nM LPI, 83 %; NMDA+10 nM LPI, 89 %; p > 0.05 vs. NMDA, respectively, 
Fig. 3.14B). 
LPI mediated neuroprotection from 0.1 nM to 10 µM. (A) LPI protected dentate gyrus granule cells in 
OHSC. LPI (1 nM - 10 µM) significantly decreased the numbers of Propidium Iodite (PI) positive 
neuronal  nuclei  after  excitotoxic  NMDA  (50  µM)  lesion  (**p  <  0.01,  ***p  <  0.001).  The 
neuroprotective effect could not be observed at 0.1 nM of LPI. (B) Microglial cells were reduced in 
LPI (0.1- 10 µM) treated OHSC leasioned with NMDA (***p < 0.001). No effect on microglia was 
observed when LPI (0.1 – 10 nM) was applied on NMDA lesioned OHSC.  
 
 
 
 
 
 
Figure 3.14  GPR55 activation mediates neuroprotection 72 
 
3.8.2  The neuronal protective effect of LPI is dependent on time and duration of LPI 
application 
Prolonged exposure to 1 µM LPI even could enhance neurotoxicity in OHSC. Application of 
1 µM LPI from div 0 until div 6, when excitotoxicity was provoked by NMDA, had no effect 
on neuronal death and microglia accumulation in the DG of OHSC (LPI (div 0-6)+NMDA, 
PI: 88 %, p > 0.05, IB4: 101 %, p > 0.05, Fig. 3.15). LPI was applied from div 0-6 and after 
NMDA treatment until  div 9, an enhanced neuronal cell death could be observed but no 
microglia alteration compared to the positive control (LPI (div 0-6)+NMDA+LPI (div 6-9), 
PI: 130 %, p < 0.05, Fig. 3.15, IB4: 116 %, p > 0.05). Applying LPI continuously from div 0, 
during  NMDA  application  and  thereafter  up  to  div  9  no  alteration  was  seen  (LPI 
(div 0-6)+NMDA/LPI+LPI (div 6-9), PI: 105 %, p < 0.05, IB4: 74%, p > 0.05). Application of 
LPI  24  h  prior  to  NMDA  application  had  no  effect  on  neuronal  death  and  microglia 
accumulation  (LPI  (24  h)+NMDA,  PI:  118  %,  p  >  0.05,  IB4:  76  %,  p>0.05).  24  h  LPI 
treatment after NMDA lesion showed a marginal decrease in neuronal lesion and microglia 
accumulation (NMDA+LPI (div 6), PI: 79 %, p > 0.05, IB4: 85 %, p > 0.05, Fig.3.15). LPI 
applied during 4h of NMDA lesion showed no effect (NMDA/LPI, PI: 111 %, p > 0.05, IB4: 
98 %, p > 0.05). Application of LPI for 9 days in non lesioned OHSC showed no effect (LPI 
(div 0-9) PI: 1 %, p > 0.05, IB4: 28 %, p > 0.05) compared to the control condition.  
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Temporal modification of LPI application changes the neuroprotective effect of LPI. 1 µM of LPI was 
applied prior to NMDA lesion from day in vitro (div) 0-6, together with NMDA (+4 h) and after 
NMDA application (24 h+ or from div 6-9).  
 
 
3.8.3  AM281 reduced the effect of LPI on microglia 
Application of AM281, a CB1 receptor antagonist, showed no neuroprotective properties at 
0.1 µM AM281 (NMDA+0.1 µM AM281, PI: 74 %, p > 0.05, IB4: 103 %, p > 0.05). 10 µM 
AM281 decreased neuronal cell death but had no effect on microglial cells in the DG of 
OHSC (NMDA+10 µM AM281, PI: 58 %, p > 0.05, IB4: 73 %, p > 0.05). Combination of 
10 µM AM281 and 1 µM LPI reduced the neuronal cell death significantly and decreased 
microglial cells in OHSC (NMDA+10 µM AM281+LPI, PI: 50 %, p > 0.05, IB4: 72 %, 
p > 0.05, Fig. 3.16).  
Application of AM281 had no effect on non damaged OHSC (PI: CTR, 2 %; LPI, 2%; 0.1 µM 
AM281, 1 %, p > 0.05; 10 µM AM281, 0 %, p > 0.05, 10 µM AM281+LPI, 0 %, p > 0.05; 
Figure 3.15  Temporal variances of GPR55 activation led to changes in neuronal cell death 74 
 
IB4: CTR, 13 %; LPI, 5%;  0.1 µM AM281, 9 %, p > 0.05; 10 µM AM281, 7 %, p > 0.05, 
10 µM AM281+LPI, 8 %, p > 0.05, Fig. 3.16). 
 
AM281 (GPR55 agonist, CB1 receptor antagonist) application on OHSC. LPI (1 µM) and AM281 
(0.1 and 10 µM) had no effect on non lesioned OHSC. Neuronal protection was observed in NMDA 
(50 µM) lesioned OHSC treated with either LPI (1 µM) or AM281 (10 µM). AM281 combined with 
LPI also reduced the number of PI positive cells in comparison with OHSC treated with NMDA 
(ANOVA, ***p < 0.001). (B) In microglia, no additional effect of AM281and LPI was seen.  
 
 
3.8.4  Combined treatment with LPI and WIN55 212-2 (WIN) enhanced neuroprotection  
OHSC treatment with NMDA and the CB1 agonist WIN significantly reduced the PI positive 
nuclei  compared  to  NMDA  (NMDA+WIN,  71  %;  p  <  0.05  vs.  NMDA,  Fig.  3.16).  The 
combination of WIN and LPI led to an additional decrease in PI positive nuclei compared to 
single WIN application after NMDA (NMDA+WIN+LPI, 48 %; p < 0.05 vs. NMDA+WIN, 
Fig. 3.17A).  
Figure 3.16  GPR55 agonist AM281 reduced neuronal cell death 75 
 
IB4  positive  microglia  were  not  decreased  when  OHSC  were  treated  with  WIN 
(NMDA+WIN, 93 % p > 0.05 vs. NMDA, Fig. 3.17B). WIN combined with LPI led to a 
decrease of microglia in OHSC (NMDA+WIN+LPI, 82 %; p < 0.05 vs. NMDA).  
WIN alone or in combination with LPI had no effect on negative control OHSC (PI positive 
nuclei: WIN, 4 %; WIN+LPI, 0 %; p > 0.05 vs. CTR; IB4 positive microglia: WIN, 17 %; 
WIN+LPI, 22 %; p > 0.05 vs. CTR). 
   
 
Combined treatment with LPI and WIN55 212-2 enhanced neuroprotection. (A) Neuronal protection 
was observed in NMDA (50 µM) lesioned OHSC treated with either LPI (1 µM) or WIN55 212-2 
(1 µM). WIN55 212-2 combined with LPI even reduced the number of PI positive cells in comparison 
with WIN55 212-2 alone in OHSC treated with NMDA (t-Test, #p < 0.05). (B) In microglial cells, no 
additional effect of WIN55 212-2 and LPI was seen, confirming the non microglial mediated WIN55 
212-2 neuroprotective effect.  
 
 
 
Figure 3.17  CB1 agonist WIN enhanced the neuronal protection of GPR55 activation 76 
 
3.9  LPI lost its neuroprotective effects after depletion of microglia  
Microglial cells were depleted in OHSC with clodronate. The neuronal cell death is increased 
in  clodronate  treated  OHSC  after  NMDA  application  (PI:  clodronate  +  NMDA,  124%; 
p < 0.01  vs.  NMDA).  LPI  lost  its  neuroprotective  effect  in  clodronate  treated  OHSC.  PI 
positive nuclei were not decreased after NMDA+LPI treatment in comparison with NMDA in 
clodronate treated OHSC (PI: clodronat+: NMDA 124 %; NMDA+LPI, 139 %; p > 0.05 vs. 
NMDA,  Fig.  3.18).  After  clodronate  treatment,  only  few  microglia  could  be  observed  in 
OHSC (IB4: clodronate treated OHSC CTR, 4 %; LPI, 3 %; NMDA 3 %; NMDA+LPI, 2 %; 
p > 0.05 vs. NMDA, compared to non clodronate treated OHSC:  CTR, 13 %;  LPI, 5 %; 
NMDA+LPI, 70 %, p < 0.01 vs. NMDA; Fig. 3.19). 
 
 
 
LPI  lost  its  neuroprotective  effects  after 
depletion of microglia. Microglial cells in 
OHSC  were  depleted  by  clodronat 
treatment. After microglial cell depletion, 
an  enhanced  neuronal  damage  after 
NMDA  (50  µM)  treatment  was  observed 
(**p < 0.01 vs. NMDA). No decrease of 
neuronal  cell  death  could  be  seen  in 
microglial  depleted  OHSC  treated  with 
NMDA and LPI (1 µM).  
 
 
 
Figure 3.18  GPR55 activation had no 
effect on microglia depleted OHSC 77 
 
 
 
 
 
 
 
 
Clodronate depleted microglia from OHSC. Microglial cells were depleted after clodronat treatement. 
Even after NMDA lesion no microglia activation could be seen.  
 
 
3.10  LPI-mediated neuroprotection and microglia reduction was reversed by 
transfection of OHSC with Gpr55 siRNA  
Treatment of OHSC with siRNA against GPR55 24 h prior to NMDA application at 6 div 
diminished the protective effect of LPI. The numbers of PI positive neuronal nuclei at 9 div in 
NMDA  and  LPI  supplemented  OHSC  were  significantly  decreased  compared  to  NMDA 
treatment alone (NMDA+LPI, 48 %; Fig. 3.20A, p < 0.001 vs. NMDA). In LPI supplemented 
OHSC microglia were decreased as well compared to NMDA (NMDA+LPI, 52 %, p < 0.01 
vs. NMDA Fig. 3.20B). OHSC treated with negRNA showed a significant decrease of PI 
positive cells after LPI treatment in comparison with single NMDA application (negRNA 
treated OHSC: NMDA 77 %; NMDA+LPI, 39 %; p < 0.01 vs. negRNA NMDA, Fig. 3.20A). 
Microglial cells were also reduced in negRNA NMDA and LPI treated OHSC compared to 
negRNA NMDA treated OHSC (negRNA treated OHSC: NMDA, 76 %; NMDA+LPI, 39 %; 
p < 0.05 vs. negRNA NMDA, Fig. 3.20B). In siRNA treated OHSC, no significant decrease 
Figure 3.19  Microglia depletion in OHSC 78 
 
in PI positive nuclei could be observed after LPI treatment in comparison to the respective 
NMDA condition (siRNA treated OHSC: NMDA, 78 % and NMDA+LPI, 64 %; p>0.05 vs. 
siRNA  NMDA,  Fig.3.20A).  Microglia  in  OHSC  treated  with  siRNA  did  not  decrease 
significantly after LPI treatment (siRNA treated OHSC: NMDA, 106 % and NMDA+LPI, 
81 %; p > 0.05 vs. siRNA NMDA, Fig. 3.20B). Non-NMDA lesioned OHSC treated with LPI 
demonstrated no alteration  in PI positive cells or in the amount of microglia (PI+: CTR was 
set to 100 %, LPI, 31 %; negRNA CTR, 109 %; negRNA LPI, 71 %; siRNA CTR, 78 %; 
siRNA LPI, 72 %; p > 0.05 vs. CTR; IB4 microglial cells: CTR was set to 100 %, LPI, 81 %; 
negRNA CTR, 98 %; negRNA LPI, 91 %; siRNA CTR, 82 %; siRNA LPI, 69 %; p > 0.05 vs. 
CTR, data not shown) 
 
 
Neuronal protection was mediated by GPR55. LPI (1 µM) mediated neuroprotection (A) and microglia 
(B)  reduction  was  reversed  by  transfection  of  OHSC  with  GPR55  siRNA.  OHSC  treated  with 
negRNA showed neuronal protection and microglia reduction by LPI treatment after NMDA (50 µM) 
lesion (***p < 0.001 vs. NMDA, **p < 0.01 vs. NMDA, *p < 0.05 vs. NMDA). In GPR55 siRNA 
treated OHSC, the neuronal protective effect as well as the reduced microglia accumulation vanished. 
Figure 3.20  Neuronal protection is mediated by GPR55 79 
 
3.10.1  Successful Gpr55 siRNA transfection was proven by semi-quantitative rt-PCR  
Down-regulation of the GPR55 expression after siRNA transfection was controlled by semi-
quantitative rt-PCR. Untreated OHSC served as controls and were set to 100 %. 24 h after 
siRNA supplementation to the culture media, a significant decrease of Gpr55 cDNA to 19 % 
(p<  0.01  vs.  untreated  OHSC,  Fig  3.21)  was  measured.  After  96  h  of  siRNA  treatment 
Gpr55 cDNA was still decreased to 35 % (p < 0.05 vs. untreated OHSC). 
  
 
GPR55  was  successfully  down-regulated.  (A) 
Successful  GPR55  siRNA  transfection  was 
proven by semi-quantitative rt-PCR. 24 h and 96 
h after GPR55 siRNA transfection GPR55 was 
downregulated  significantly  (**p  <  0.01, 
*p < 0.05, n = 3).  
 
 
 
 
 
 
 
 
Figure 3.21  GPR55 was down-regulated 
after siRNA transfection 80 
 
3.11  Gpr55 mRNA in OHSC, primary microglia and astroglia after LPI 
treatment  
In primary astrocyte cell culture, GPR55 was down-regulated after 10 ng/ml LPS and 1 µM 
LPI.  Control  primary  astrocyte  cell  culture  was  set  to  100  %  (LPI,  128  %;  LPS,  85  %; 
p > 0.05 vs. CTR, and LPS+LPI, 43 %, p < 0.05 vs. CTR independent t-Test, Fig. 3.22A). 
GPR55  was  downregulated  in  primary  microglia  culture  treated  with  LPI  (1  µM),  LPS 
(10 ng/ml) and LPS+LPI compared to control cultures (LPI, 54 %; LPS, 43 %; LPS+LPI, 
55 %, p < 0.001 vs. CTR, Fig. 3.22B) 
LPI influenced GPR55 expression in primary glia cell culture. (A) Primary astrocyte culture was 
treated with LPI (1 µM), or/and LPS (10 ng/ml) for 6 h. Only LPS in combination with LPI led to a 
decrease in GPR55 expression (**p < 0.01). (B) In primary microglia, LPI and LPS reduced GPR55 
expression significantly (*p < 0.05). No enhanced GPR55 down-regulation was observed by combined 
LPS and LPI treatment. (n = 3)  
 
 
Figure 3.22  GPR55 expression in primary glia cell cultures 81 
 
3.12  LPI attenuated ATP- and LPI- induced microglia migration  
LPI (1 µM), ATP (100 µM) and LPS (10 ng/ml) increased the migration of primary microglia 
in  Boyden  chamber  experiments  significantly  (CTR,  10.48/well;  LPI,  21.23/well;  ATP, 
24.22/well, LPS, 23.55/well p < 0.01 vs. CTR). The enhanced motility of ATP and LPS was 
reduced by LPI addition back to LPI counts (LPI+ATP, 19.41/well; LPI+LPS, 18.57/well; 
p < 0.05  vs.  ATP  and  LPS  respectively,  Fig.  3.23A,B).  Control  experiments  with  equal 
substance distribution reduced the migration to control levels (CTR, 7.50/well; LPI, 7.33/well; 
ATP, 6.60/well; LPI+ATP, 6.33/well; p > 0.05 vs. CTR, data not shown). The CB1 antagonist 
AM281 enhanced migroglia migration but did not change the effect of LPI (CTR, 11.53/well; 
LPI,  17.26/well;  AM281,  18.77/well;  LPI+AM281,  17.76/well,  p  <  0.05  vs.  CTR, 
Fig. 3.23C). 
   
 
 
 
 
 
 
 LPI  enhanced  primary  microglia  migration.  Using  Boyden  Chamber,  single  LPI  (1  µM)  ATP 
(100 µM) or LPS (10 ng/ml) supplementation to primary microglial cell culture increased the number 
of  migrating  microglial  cells  compared  to  untreated  control  microglial  cells  (***p  <  0.001).  
Combining LPI and ATP reduced the migratory effect of primary microglial cells (*p < 0.05). The 
migratory  effect  was  lost  when  the  substances  were  applicated  in  the  upper  chamber  as  well. 
Combining LPI and LPS reduced the migratory effect of primary microglial cells as well as ATP 
(*p < 0.05). (C) No modification of migration induced by LPI was seen when CB1 antagonist was 
applied. 
Figure 3.23  GPR55 activation on microglia migration 82 
 
4.  General Discussion 
 
The present dissertation investigated the regulation of the endocannabinoid system after long 
range  projection  damage  and  excitotoxic  lesion  and  the  impact  of  GPR55,  a  potent 
cannabinoid  receptor,  during  excitotoxic  lesion.  The  present  studies  were  conducted  with 
organotypic hippocampal slice cultures (OHSC) in vitro. In OHSC the neuronal circuit is 
preserved during culture and allows identifying properties of neuronal tissue, neurons and 
glial cells. (Adamchik, Frantseva et al. 2000; Hailer, Wirjatijasa et al. 2001; Adembri, Bechi 
et al. 2004). 
 
4.1  Perforant Pathway transection model modification 
The PPT model in OHSC has been extended by precise dissection of the affected areas to 
investigate the intrinsic regulation of endocannabinoids after axonal (retrograde) damage and 
dendritic denervation (anterograde damage) of the perforant pathway, a long-range projection. 
The  PPT  model  and  the  subsequent  precise  dissection  of  the  anterograd  and  retrograde 
lesioned regions was successfully applied and the eCB content could be determined. After 
denervation neurons undergo complex reorganization processes. It could be shown that the 
dissection of entorhinal afferents induced dendritic changes of the granular cell layer of the 
dentate gyrus (Diekmann, Ohm et al. 1996; Vuksic, Del Turco et al. 2011). Neuronal cell 
death was not induced by deafferentiation of the granular cell layer as also described earlier in 
an in vivo model (Kovac, 2004). Glial cells became activated and covered the lesion sites, 
peviously neurite sprouting was observed after astrocyte hypertrophy and astrocyte derived 
factors were supposed to influence neuronal growth after deafferentiation (Ide, Scripter et al. 
1996). 83 
 
4.2  Endocannabinoid regulation after perforant pathway transection 
CNS  pathologies  induce  direct  neuronal  tissue  damage  that  also  involves  long  range 
projection  deafferentiation,  but  also  indirect  lesioned  areas  become  severely  affected  in 
secondary damage regulation. Small but not significant changes were observed in the EC, 
whereas a significant and robust increase in the concentration of all investigated eCB was 
found 24hpl in the DG. These findings indicate a spatial and temporal regulation of eCB 
mostly  affecting  the  target  area  of  long-range  projections.  In  several  reports  enhanced 
anandamide and 2-AG levels have been detected after various pathological events, like stroke, 
traumatic brain injury e.g., indicating a compensatory mechanism to brain damage (Hansen, 
Schmid et al. 2001; Maccarrone, Gubellini et al. 2003; Marsicano, Goodenough et al. 2003).  
 
 
 
 
 
 
ECB were up-regulated in the DG, after perforant pathway transection.  Only the anterograde lesion 
site showed an alteration of eCB levels after PPT. EC entorhinal cortex, CA1 cornue ammonis region 
1, DG dentate gyrus, PPT perforant pathway transsection. 
 
It was previously shown that anandamide and 2-AG activate MKP-1 in microglia, abolishing 
NO release and protected against over-activation of microglia (Dommergues, Plaisant et al. 
Figure 4.1  Anterograde signallin of endocannabinoids 84 
 
2003; Eljaschewitsch, Witting et al. 2006). Therefore, the increased eCB levels 24hpl in our 
study might reduce the microglia activation leading to neuroprotective effects. However, cell 
culture  experiments  with  BV-2  cells  showed  an  increase  in  microglia  motility  after 
anandamide supplementation (Franklin, Parmentier-Batteur et al. 2003). Still, enhanced OEA 
levels, also observed in the present study were found to further reduce microglia activation 
(Coffey,  Perry  et  al.  1990;  Topper,  Gehrmann  et  al.  1993).  The  inhibition  of  reactive 
microglia by OEA might therefore conduct neuroprotective effects. Also PEA was shown to 
be potent to prevent neuronal damage by activation of PPARalpha in microglia. PEA however 
stimulated also PPARalpha in neurons and astrocytes (Koch et al., 2011, Raso et al., 2011). 
Similar  to  the  elevated  anandamide  levels  in  the  cerebrospinal  fluids  after  stroke  or  in 
Parkinson  disease  (Schabitz,  Giuffrida  et  al.  2002;  Pisani,  Fezza  et  al.  2005),  increased 
anandamide and PEA levels were observed in the present study 24hpl. Enhanced PEA levels 
were also measured in inflamed tissues undergoing severe cell damaging processes, ischemic 
conditions  and  glutamate  induced  neurotoxicity  demonstrating  neuroprotective  properties 
(Rodriguez De Fonseca, Gorriti et al. 2001; Conti, Costa et al. 2002; Koch, Kreutz et al. 
2011).  The  combined  up-regulation  of  anandamide  and  PEA,  the  previously  described 
entourage effect could have served also in the present study to enhanced action of anandamide 
at the CB1 and the vanilloid receptor (De Petrocellis, Davis et al. 2001). The simultaneously 
enhanced  OEA  levels  24hpl  in  the  present  study  is  in  line  with  a  previous  study,  where 
dopamine  neurons  of  the  substantia  nigra  were  protectd  by  OEA  after  a  treatment  with 
6-OHDA (Galan-Rodriguez, Suarez et al. 2009). 2-AG regulation after PPT in OHSC, also 
differentiated  clearly  the  lesion  sites.  It  could  be  shown  that  the  indirect  dendritic  lesion 
resulted in a moderate 2-AG increase in the DG and had no further effects on 2-AG regulation 
in  the  CA1  region.  2-AG  is  commonly  accepted  as  an  important  component  of  the 
endocannabinoid  system  protecting  neurons  after  neuronal  insults  by  retrograde  signaling 85 
 
decreasing neuronal excitation (Panikashvili, Simeonidou et al. 2001; Marsicano, Moosmann 
et al. 2002; Milton 2002; van der Stelt and Di Marzo 2005). The elevation observed in the 
present study might therefore indicate a neuroprotective reaction at the anterograde lesion site 
after PPT. However, the overall increase of eCB at the anterograde lesion site could further 
indicate an involvement of eCB in dendtitic re-organisation.  
 
4.3  Endocannabinoid regulation after excitotoxic lesion 
The  excitotoxicity  model  with  NMDA  was  used  to  investigate  whether  different  OHSC 
regions would respond with different eCB levels to low or high concentrations of NMDA.  
Surprisingly, the EC did not react to low or high NMDA lesion with altered 2-AG levels but 
with  enhanced  levels  of  NEA  after  high  NMDA  treatment.  Enhanced  eCB  levels  were 
measured 24 hours after low and high NMDA lesion in the DG. Though, low NMDA doses 
enhanced  eCB  levels  significantly  in  the  CA1  region.  Being  the  region  with  the  highest 
density of NMDA receptors the CA1 region is the most sensitive region to excitotoxic lesion 
(Kristensen, Noraberg et al. 2001). Evidence exists that the density of the 2-AG hydrolyzing 
enzyme,  MAGL,  is  low  on  the  axon  terminals  of  mossy  cells  and  DAGL,  the  2-AG 
synthesising enzyme, was shown to be abundant at the Schaffer collateral CA1 region of the 
hippocampal formation (Katona, Urban et al. 2006; Ludanyi, Hu et al. 2011; Uchigashima, 
Yamazaki et al. 2011). This strengthens the relevance of 2-AG in the CA1 region during 
neuronal  stress.  Enhanced  eCB  response  to  low  NMDA  excitotoxic  damage  might  be  a 
possible mechanism to counteract the insult in the more susceptible CA1 region. Stimulation 
of the Schaffer collateral synapses shown by Stella et al. led also to an endogenous 2-AG 
release in rat OHSC (Stella, Schweitzer et al. 1997) and also short-term synaptic depression 
was consistently enhanced by inhibition of MAGL (Pan, Wang et al. 2011; Straiker, Wager-
Miller et al. 2011) supporting the present data. In vivo models of closed head injury and focal 86 
 
ischemia in mice reported intrinsic elevated 2-AG levels after 4 and also after 1 to 24 hours 
post  lesion  (Panikashvili,  Simeonidou  et  al.  2001;  Degn,  Lambertsen  et  al.  2007).  This 
variances in 2-AG regulation might be partly provoked by the blood-brain barrier (BBB) 
disruption, as enhanced 2-AG levels were shown to reduce BBB permeability 1-4 hours after 
brain injury (Panikashvili, Shein et al. 2006; Degn, Lambertsen et al. 2007). However, the 
diverse regulation of eCB in different brain regions after PPT and after excitotoxic lesion 
demonstrates  a  specific  involvement  of  eCB  in  distinct  damage  regulation  in  the  brain. 
Whether  eCB  are  involved  in  different  neuronal  protection  mechanisms  needs  however 
further investigation. The difficulty to interpretate PEA and OEA together with anandamide is 
due to their structural similarity and comparable regulation (Hansen 2010), that is also seen in 
the present study. 
 
4.4  Enzymatic regulation of eCB after PPT 
As a next step the time-dependent and spatial regulation of enzymes responsible for synthesis 
and hydrolysis of the eCB in the PPT model was investigated, as the lesion sites were clearly 
differentially regulated.  
Enzymatic regulation of NEA 
NAPE-PLD,  synthesising  NEA  from  NAPE  (Okamoto,  Morishita  et  al.  2004;  Leung, 
Saghatelian et al. 2006), was elevated early between 1hpl and 6hpl after PPT but decreased to 
control  levels  at  72  hpl.  The  augmentation  of  NAPE-PLD  might  explain  the  NEA 
accumulation 24 hours after PPT. However two further enzymes were found that may present 
an alternative pathway for NEA synthesis and were not investigated in the present study. 
Phospholipase C (PLC) can synthesise phosphor-NEA, which is then hydrolysed to NEA and 
the two enzymes phospholipase B (ABDH4) and the phosphodiesterase (GDE1) can together 87 
 
hydrolyse  glycerophospho-NAE (GP-NAE) to  NEA  (Sun, Tsuboi  et  al.  2004; Simon and 
Cravatt 2008). The alternative enzymes were taken into consideration after it could be shown 
in  2011  by  Zhu  et  al.  that  mice  lacking  NAPE-PLD  were  able  to  synthesise  PEA  (Zhu, 
Solorzano et al. 2011). Whether these alternative pathways become active when NAPE-PLD 
gain  its  functionality  or  whether  they  display  only  a  compensatory  mechanism  in  NEA 
synthesis, still remains unclear. In a study with macrophage cell culture, lipopolysaccharide 
(LPS) reduced the amount of NAPE-PLD and therewith the amount of PEA, subsequently 
leading  to  enhanced  inflammatory  reactions  (Zhu,  Solorzano  et  al.  2011).  The  cellular 
distribution of NAPE-PLD displayed a clear neuronal localisation that was earlier described 
(Nyilas, Dudok et al. 2008). NAPE-PLD immunoreactivity was seen in primary microglia in 
culture and microglia in OHSC, although astrocytes in culture expressed NAPE-PLD but not 
in OHSC. In a postmortem study of MS patients, NAPE-PLD expression could be found in 
microglia as well as in astrocytes (Zhang, Hilton et al. 2011). Whether the expression of 
NAPE-PLD  in  MS  indicates  a  dysregulated  endocannabinoid  system  or  an  appropriate 
response to compensate the pathologic inflammation in these patients remains ambiguous. 
The hydrolysing enzyme FAAH was found being predominantly localised in the endoplasmic 
reticulum (Cravatt, Giang et al. 1996) and is able to hydrolyse all three acylethanolamides 
investigated in this work (Ueda, Tsuboi et al. 2010). The high FAAH expression observed at 
48 hpl might explain the down-regulation of all investigated NEA back to control levels or 
even decreased levels. The FAAH inhibitors MAFP or URB597 enhance NEA levels in vivo 
and in vitro and MAFP was found to reduce apoptosis in the neocortex (Maccarrone, Piccirilli 
et al. 2004) and URB 597 decreased the infarct volume when administered prior to focal 
cerebral ischemia (Degn, Lambertsen et al. 2007). The amount of FAAH was observed to 
correlate with neurotoxic properties (Degn, Lambertsen et al. 2007). Other FAAH inhibitors 
were found to be beneficial for the outcome of neurological diseases as well (Fowler, Rojo et 
al. 2010). FAAH was clearly expressed in neurons of OHSC, confirming previously reported 88 
 
data by Cravatt et al. (Cravatt, Giang et al. 1996). In OHSC, FAAH could not be detected in 
microglia neither in PPT nor in controls, whereas primary microglia cell cultures expressed 
FAAH as shown previously (Witting, Walter et al. 2004; Tham, Whitaker et al. 2007). A 
previous report of Alzheimer disease patients showed that FAAH is expressed in astrocytes. 
In the present study, low FAAH expression in fibrillary astrocytes and high FAAH expression 
were found in protoplasmic astrocytes of primary cell cultures  but not  in OHSC (Nunez, 
Benito et al. 2008). However, further investigations are required to figure out whether the here 
observed  endogenous  up-regulation  of  FAAH  determines  the  eCB  involvement  in 
inflammatory reactions and for which reason. Thus, the question remains whether the intrinsic 
down-regulation of eCB happens due to the inflammatory status or whether prolonged eCB 
activation could have positive effects as indicated in literature (Fowler et al., 2010).    
Another recently discovered enzyme is  NAE-hydrolysing acid  amidase (NAAA)  that was 
detected in lysosomes of HEK cells (Zhao, Tsuboi et al. 2007).  This enzyme is responsible to 
hydrolyse acylethanolamides of less than 18 carbon atoms, including PEA. However, NAAA 
protein expression remained unchanged at any time point after PPT in the present study. The 
imunohistochemical distribution of NAAA in brain tissue is described here for the first time. 
NAAA  was  expressed  in  neurons  of  OHSC  and  primary  neuronal  cultures.  Microglia  in 
OHSC showed no NAAA expression although NAAA was described in macrophages as a 
lysosome  associated  protein  (Ueda,  Tsuboi  et  al.  2010).  In  primary  cultures  fibrillary 
astrocytes showed high NAAA expression whereas protoplasmic astrocytes displayed only 
weak NAAA in their nuclei only.  
Taken  together,  the  different  expression  patterns  of  NAPE-PLD,  FAAH  and  NAAA  in 
primary cell culture and OHSC, especially found in  microglia, might  be due to  the tight 
functional connection of the glia cells and neurons with each other. This interplay determines 
the state of activation, especially of microglia (Schafer, Lehrman et al. 2012). Thus, NEA can 89 
 
be synthesised and hydrolysed not only by neurons but also by glial cells under physiological 
and pathological conditions, indicating the importance of the eCBS in pathological changes 
and underlining its high dynamic. The present results indicate that the different cell types are 
potent to alter their eCB content depending on circumstances and environment. The lack of 
neuronal contact is suggested to lead to enhanced eCB production of glia cells which opens a 
new perspective of the eCBS and still needs to be investigated.   
No obvious redistribution of CB1 in lesioned dendrites of the molecular layer or glial cells 
could be observed in slice cultures undergoing PPT. Although eCB and the specific enzymes 
become altered after PPT in OHSC, the main target receptor of the investigated eCB, CB1, 
remained quantitatively unchanged. Still, the CB1 could be re-distributed and more cellular 
investigation is needed to understand the precise mechanism.  
 
Enzymatic regulation of 2-AG  
The involvement of the main synthesising (DAGL) and hydrolysing (MAGL) enzymes of 
2-AG were investigated. Dagl mRNA amounts were unchanged after PPT in the EC and were 
enhanced 24 hpl in the DG, whereas Magl mRNA remained at control levels. Increased Dagl 
mRNA  levels  could  explain  the  enhanced  2-AG  levels  of  the  anterograde  lesion  site  as 
suggested by a previous spinal cord study (Garcia-Ovejero, Arevalo-Martin et al. 2009). The 
investigated DAGL protein levels over time however, showed a decreased DAGL protein 
expression  24  hours  after  PPT.  Opposed  expression  of  Dagl  mRNA  and  DAGL  protein 
expression with increased 2-AG levels might still be explained by DAGL ubiquitination, as 
DAGL  is  involved  in  highly  dynamic  processes  e.g.  development,  axonal  growth  and 
orientation (Bisogno, Howell et al. 2003; Walker, Suetterlin et al. 2010). Therefore, DAGL 
needs to be expressed in a quickly regulated mechanism like ubiquitination. It was shown that 
ubiquitination was important in the regulation of fast turnover of signaling events and plays a 90 
 
fundamental role in signal transduction, cell cycle regulation and transcription  (Wickliffe, 
Williamson et al. 2009; Clague and Urbe 2010). Recently, two enzymes (Phospholipase D1, 
Cyclooxygenase-1  (COX-1))  involved  in  arachidonic  acid  regulation  were  shown  to  be 
ubiquitinated (Yin, Gui et al. 2010; Yazaki, Kashiwagi et al. 2012). In human embryonic 
kidney  cells,  intra-cellular  calcium  concentration  COX-1  degradation  was  shown  to  be 
regulated by ubiqitination. (Yazaki, Kashiwagi et al. 2012). As 2-AG is regulated calcium 
dependent in excitotoxic neuronal damage, this might be another indication for an ubiquitin 
involved mechanism.  
The  regulation  of  DAGL  and  MAGL  was  investigated  under  control  and  stimulated 
conditions  in  OHSC  as  well  as  in  primary  cell  cultures  on  their  cellular  distribution  in 
neurons, microglia and astrocytes. DAGL could be observed in neurons and only marginal in 
astrocytes of OHSC. In primary neuronal cultures, DAGL co-localised with Vglut1 at the 
presynapse. Previously, DAGL was  localised in cerebellar, hippocampal and striatal neurons 
at the dendritic spines in the CA1 subfield, linked to the intracellular surface of the plasma 
membrane (Katona, Urban et al. 2006; Yoshida, Fukaya et al. 2006; Uchigashima, Narushima 
et  al.  2007;  Uchigashima,  Yamazaki  et  al.  2011).  A  re-organisation  of  DAGL  after  PPT 
towards the lesioned dendrites was observed in the present study, but interestingly the DAGL 
immunoreactions in astrocytes increased. Gomez et al., showed that GFAP positive cells can 
be DAGL immunoreactive (Gomez, Arevalo-Martin et al. 2010) sustaining the present data. 
Further, astrocytes were shown in the epicenter of spinal cord injury to be DAGL positive 
(Garcia-Ovejero, Arevalo-Martin et al. 2009). The expression of DAGL in astrocytes is in line 
with previous reports describing an intense 2-AG production of astrocytes when stimulated in 
vitro with inflammatory mediators (Franklin, Parmentier-Batteur et al. 2003; Walter, Franklin 
et al. 2003). In microglia however, no DAGL IR in OHSC, but in primary microglia culture 
was observed. In previous studies, 2-AG was also shown to be produced by microglia cultures 91 
 
in vitro (Walter, Franklin et al. 2003; Witting, Chen et al. 2006). However, in an in vivo study 
of spinal cord injury no DAGL IR could be observed in microglia (Garcia-Ovejero, Arevalo-
Martin et al. 2009) like in the present study.  
The distribution of the degrading enzyme MAGL displayed a re-organisation. Most studies 
focused on the neuronal expression pattern of MAGL, however the cellular expression of 
MAGL  during  NMDA  lesion  and  PPT  showed  a  very  low  expression  of  MAGL  IR  in 
astrocytes compared to the controls. It has been previously reported that astrocytes express the 
degrading enzyme MAGL as reviewed by Stella (Stella 2004; Fernandez-Ruiz, Pazos et al. 
2008). The here observed MAGL expression during neuronal damage demonstrates the high 
impact of 2-AG and that astrocytes are highly involved in 2-AG break-down. However, this 
result still needs to be supported by in vivo experiments. Further, it indicates that glia cells 
might have a greater role in eCB regulation as indicated by literature.  
MAGL IR of microglia was not found in OHSC but in primary cell culture. Likewise, the 
regulating  enzymes  of  NEA  microglia  are  potent  to  determine  eCB  regulation  but  the 
environmental signals still remain unknown. Studies suggest that approx. 9 % of total 2-AG 
hydrolysis  in  brain  is  ABHD12  dependent,  which  is  highly  expressed  in  microglia 
(Savinainen, Saario et al. 2012). Further, MAGL and ABHD12 were suggested as analogues 
for brain  microglia  or  monocytes in  related  cell types of peripheral  tissues  (Fiskerstrand, 
H'Mida-Ben Brahim et al. 2010). ABHD12 was however not investigated in the present study. 
During  different  cellular  activation  state,s  DAGL  IR  and  MAGL  IR  were  differentially 
expressed, suggesting a defined expression pattern. Thus, a highly defined regulation of 2-AG 
in different neurotoxic conditions is suggested.   
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4.5  Regulation of CB1 and PPARalpha after PPT in OHSC 
The regulation of CB1 was enhanced in the EC early after PPT and in the CA1 region at a 
later  time  point.  However,  in  the  region  of  eCB  up-regulation,  the  DG,  CB1  showed  no 
alteration.  A previous study on rats observed only an up-regulation of CB1 expression from 
2 h after middle cerebral artery occlusion up to 72 h in the direct ischemic region (Jin, Mao et 
al. 2000). The effect of ischemic insults upon CB1 however, is unclear and seems to depend 
on ischemic condition, time and species investigated (Fowler, Rojo et al. 2010). Studies of 
differentially  regulated  CB1  receptors  on  glutamatergic  and  GABAergic  synapses  might 
clarify these coherences (Marsicano, Goodenough et al. 2003). Recently, evidence showed 
that  GABAergic  interneurons  of  the  hippocampus  synthesise  2-AG,  although  a  higher 
excitation stimulus is needed compared with glutamateric neurons (Peterfi, Urban et al. 2012).  
CB1 and DAGL are evolutionary related, stating 2-AG as the endogenous ligand for CB1 
(McPartland, Norris et al. 2007; Katona and Freund 2008). This might indicate a synergistic 
regulation.  However,  the  regulation  of  CB1  during  neuronal  damage  needs  further 
investigation.  Cravatt et al. showed that after prolonged 2-AG stimulation, compensatory 
desensitization of the CB1 receptor in the brain, like CB1 receptor density and functional 
responses were attenuated (Schlosburg, Blankman et al. 2010). In the present model however, 
no  up-regulation  of  DAGL  or  down-regulation  of  MAGL  was  observed.  The  intrinsic 
augmentation of anandamide and 2-AG have not influenced the CB1 expression in the DG, 
altough  the  CB1  alteration  in  the  EC  and CA1  region  might  be  a  response  to  axonal  re-
orientation.  
A nuclear receptor for NEA is PPARα (De Petrocellis, Chu et al. 2004; Suardiaz, Estivill-
Torrus  et  al.  2007).  Application  of  exogenous  PEA  was  reported  to  enhance  PPARα 
activation. Selective NAAA inhibitors were able to up-regulate the endogenous PEA levels 
and subsequently increase PPARα activity (Lo Verme, Fu et al. 2005; Solorzano, Zhu et al. 93 
 
2009). However, no alteration of PPARα could be observed after PPT in OHSC although PEA 
was up-regulated 24 hours post lesion.  
 
4.6  2-AG mediates neuroprotection 
2-AG was shown to be endogenously up-regulated at the anterograde lesion site 24 hpl after 
PPT in OHSC. Supplemented 2-AG is seen as a modulator of neuroprotection which could be 
shown in a previous study of excitotoxic damage in OHSC (Kreutz, 2009). DAGL -/- mice 
had  reduced  2-AG  levels  and  it  was  shown  that  2-AG  was  involved  in  neurogenesis 
(Goncalves, Suetterlin et al. 2008; Gao, Vasilyev et al. 2010). The anterograde up-regulation 
of 2-AG after PPT might indicate a further role of 2-AG in dentritic protection, not only after 
excitation  as  shown  by  Kantona  and  Freund  (2008).  In  a  different  approach,  the  MAGL 
inhibitor JZL184 was used here to induce an endogenous increase in 2-AG levels to reduce 
neuronal damage. The increase of 2-AG after JZL184 supplementation in the present study 
was similar to the increase reported in former studies where chronic JZL184 supplementation 
inactivated MAGL and subsequently led to a 10-fold increase of 2-AG levels in brain and 
spinal cord tissue (Chanda, Gao et al. 2010; Savinainen, Saario et al. 2012). A lower 2-AG 
increase in the CA1 region after PPT than in the DG and the EC was observed, supporting the 
data that less MAGL is present in the CA1 region (Katona, Urban et al. 2006; Ludanyi, Hu et 
al. 2011; Uchigashima, Yamazaki et al. 2011). 
Here, excitotoxic lesioned OHSC were treated with JZL184 or MAGL siRNA to investigate 
whether this MAGL inhibition indeed can induce neuroprotection. The neuronal damage of 
the  granular  cell  layer  decreased  remarkably,  as  was  also  shown  by  other  studies,  which 
demonstrates the neuroprotective properties of endogenous and exogenous 2-AG in neuronal 
excitotoxic models and other cellular settings (Zhao, Yuan et al. 2010; Koch, Kreutz et al. 
2011).  94 
 
Summarizing, the intrinsic activation of the eCBS after neuronal damage by transection of 
long-range projections and excitotoxic damage within secondary damage regulation, provides 
a strong time-dependent and site-specific signal for endogenous synthesis of eCB, presumably 
to prevent or restrict neuronal damage. Furthermore, the regulation of eCB underlines their 
importance in CNS pathologies that involves a dynamic and complex interplay mainly of 
astrocytes and neurons, depending on time and cellular organization. 
 
 
 
 
 
 
 
 
 
Schematic drawing of neurons and glial cells and their potential of eCB regulation after neuronal 
damage.  Neurons,  astrocytes  and  microglia  are  potent  to  regulate  2-AG.  NEA  are  regulated  by 
neurons. Glial cells have the capacity to break down NEA.  (arrows indicate the degree of potention)   
Figure 4.2  Schematic drawing of the endocannabinoid regulation in different cellular populations 95 
 
4.7  GPR55 mediates neuroprotection in excitoxically lesioned OHSC through 
microglia  
Besides  CB1  and  CB2,  GPR55  has  recently  been  identified  to  become  activated  by 
endocannabinoids  and  is  now  discussed  as  a  potential  cannabinoid  receptor.  GPR55  was 
cloned in 1999 and an in silico screening revealed a ligand-binding region in GPR55 very 
similar to that of CB1/CB2 (Henstridge, Balenga et al. 2010). It was suggested earlier that 
additional receptor subtypes than CB1 and CB2 belong to the targets of eCB and are associated 
with neuroprotection (Begg, Pacher et al. 2005). Recently, the GPR55 receptor is discussed as 
a novel CB receptor subtype (Stella 2010). Endocannabinoids activate the CB1/CB2 but also 
the transient receptor potential vanilloid-1 (TRPV1) and yet unknown receptors. The cluster 
”endocannabinoids” might therefore be only a superficial categorisation and sometimes even 
misleading.  Lipid  signaling  network  is  much  more  complex  and  reflects  often  a  broader 
interaction than the present nomenclature indicates. Therefore, it might be misleading when 
substances and receptors are directed to one or the other system and provoke the impression 
that the different systems do not highly interact with each other.  
Acute and chronic CNS pathologies lead to intensive searches for drugs and targets that might 
reduce the detrimental outcome of CNS damage, especially of the secondary damage impact 
(Dumont,  Okonkwo  et  al.  2001).  ECB  and  the  CB  receptors  are  shown  to  mediate 
neuroprotection in excitotoxic neuronal damaged OHSC, likewise the GPR55 receptor ligand 
lysophosphatidylinositol  (LPI)  was  applied  to  investigate  the  potency  of  GPR55  on 
neuroprotection. GPR55 besides eCB, is also a target of the phospholipid LPI, which has been 
identified as the best characterised agonist of GPR55, and the onewith the highest activation 
rate  (Oka  et  al.,  2007).  Together  with  the  well  studied  glycerophospholipids  and 
sphingolipids, LPI belongs to the group of lysophospholipids. In brain tissue, considerable 
levels of LPI (37.5 nmol/g tissue) are present; and GPR55 is expressed at high levels in the 96 
 
central  nervous  system  (Pineiro  and  Falasca  2012).    Although  GPR55  has  been  studied 
intensively and pharmacological evidence exists for being an additional cannabinoid receptor, 
LPI was used in the present model to identify the potential neuroprotective effect of GPR55. 
Interference with concomitant activation of CB1/CB2 by eCB was herewith prevented.  
Less neuronal damage and fewer microglial cells were dose-dependently observed after LPI 
(0.1 nM  -  10  µM)  treatment.  In an  earlier study,  LPI (10 µM) was  observed to  mediate 
neuroprotection in excitotoxic lesioned cultures of cerebellar granule cells and after cerebral 
ischemia  in  rats  without  knowing  the  specific  receptor  mediating  this  effect  (Blondeau, 
Lauritzen et al. 2002). Using Gpr55 siRNA, it was shown that GPR55 is one responsible 
receptor  for  the  LPI  induced  neuroprotection  in  excitotoxically  lesioned  OHSC,  as  no 
neuronal protection and microglia accumulation could be observed in OHSC any longer.  
However, LPI/GPR55 activation was only neuroprotective when applied for three days after 
excitotoxic damage was induced and lost its neuroprotective effect depending on temporal 
administration.  No  protective  effect  was  seen  after  pre-treatment  or  simultaneously 
application of LPI during excitation. After prolonged administration of LPI thoughout the 
culture  periode  and  the  entire  experiment,  an  even  enhanced  neuronal  damage  could  be 
observed. It could be assumed that enhanced exposure to LPI decreases cellular sensitivity, 
disabling  important  protective  mechanisms  like  calcium  regulation  mediated  by  GPR55. 
Endocannabinoids,  phytocannabinoids  and  synthetic  cannabinoids  were  shown  to  activate 
GPR55 in the nM as well as in the µM range when GPR55 was over-expressed in different 
cell lines (Sawzdargo, Nguyen et al. 1999; Baker, Pryce et al. 2006; Ryberg, Larsson et al. 
2007; Pietr, Kozela et al. 2009; Ross 2009). This evidence led to the hypothesis that eCB 
might influence the effects of LPI/GPR55 but also might influence their own effectiveness. A 
very  recent  study  suggests  the  interaction  of  GPR55  and  CB1,  although  this  study  was 
conducted with HEK cells over-expressing GPR55 and CB1 (Kargl, Balenga et al. 2012). 97 
 
AM281, a CB1 antagonist and potential GPR55 agonist, was tested on excitotoxically lesioned 
OHSC. AM281 reduced the number of dead neurons independent of LPI administration and 
microglia  were  less  reduced  than  compared  to  LPI  treatment.  Meanwhile  the  activity  of 
AM281 is discussed in literature wheather it is a ligand at GPR55  or not, as studies were 
mostly  conducted with  transfected cell lines  (Sharir and Abood 2010). WIN55 212-2, an 
approved CB1 agonist in synergism with LPI enhanced the neuronal protection in OHSC, 
although  microglia  were  not  down-regulated.  This  suggests  that  CB1  and  GPR55 
independently  regulate  neuroprotective  mechanisms  leading  to  favorable  effects.  The 
neuroprotective effect of LPI and the simultaneously decreased microglia, together with the 
recent finding of GPR55 in the mice microglia cell line BV-2 and in primary microglia (Pietr, 
Kozela  et  al.  2009),  was  followed  by  the  investigation  of  the  role  of  microglia  in 
excitotoxically lesioned OHSC. Subsequently, the effect of LPI in microglia depleted OHSC 
on behalf of clodronate was investigated and counteracted the neuroprotective activation of 
GPR55 by LPI.  
In regard to the decreased microglia number in OHSC as well as changes in receptor mRNA 
level the effect of LPI on migration of primary microglia was investigated. Interestingly, LPI 
reduced ATP and LPS induced migration, however, LPI was chemoattractive itself, showing 
migratory effects of LPI on primary microglia for the first time. Here it should be mentioned 
that the potency of LPS to attract microglia cannot be fully explained and opens a different 
field  of  investigation  and  considerations  beyond  the  present  work.  Direct  treatment  of 
microglia with LPS however, was shown to enhance microglia migration (abd-el-Basset and 
Fedoroff 1995). Within the brain, microglia are defined as an indispensible player in both 
beneficial and detrimental  inflammatory  cascades  that determine the final  outcome in  the 
context of brain diseases (Hanisch and Kettenmann 2007). Many studies support the idea that 
glial cells are crucially involved in secondary neuronal damage that follows to the initial 98 
 
neuronal lesion (Sawada, Kondo et al. 1989; Moss and Bates 2001; Streit 2002). On the other 
hand,  literature  underlines  as  well  that  microglia  exert  neuroprotective  effects  after  CNS 
lesions (Kohl, Dehghani et al. 2003; Simard, Soulet et al. 2006). Recent studies showed a 
broad range of evidence that LPI enhances proliferation of different cell types, especially 
demonstrated in cancer cell lines by various groups, summarised recently by Pi eiro et al. 
(2012). There, it was demonstrated that LPI has a role in migration and orientation of human 
breast cancer cells by GPR55 activation (Ford, Roelofs et al. 2010) and that LPI, together 
with GPR55, are involved in an autocrine loop regulating the proliferation of prostate and 
ovarian cancer cells (Pineiro, Maffucci et al. 2011). Also clinical evidence demonstrates that 
patients with ovarian cancer or peritoneal cancer had higher accumulated levels of LPI in 
blood and ascites than healthy controls (Xiao, Chen et al. 2000; Xiao, Schwartz et al. 2001; 
Xu, Xiao et al. 2001). However, it was recently shown that neutrophils migrate towards LPI 
and the more stable synthetic cannabinoid GPR55 agonist AM251 (Henstridge, Balenga et al. 
2010; Balenga, Aflaki et al. 2011).  
Another study showed an effect of LPI/GPR55 mediated Ca
2 + regulation in endothelial cells 
(Waldeck-Weiermair,  Zoratti  et  al.  2008;  Bondarenko,  Waldeck-Weiermair  et  al.  2010). 
Primary  sensory  neurons  were  observed  to  release  intracellular  calcium  ([Ca
2+]i)  and  to 
diminish their M-type potassium currents upon GPR55 activation (Lauckner, Jensen et al. 
2008).  Ca
2 +  mobilisation  from  intracellular  stores  and  membrane  hyperpolarisation  were 
inhibited upon GPR55 antagonist supplementation (Falasca, Silletta et al. 1995). Further, in 
rat liver mitochondria, LPI regulated calcium transport, inducing both uptake and release of 
Ca
2 + (Dalton, Hughes et al. 1984; Lenzen, Gorlich et al. 1989). Although it is not clarified 
yet, whether calcium dependent exocytosis is mediated by GRP55 (Ma, Yeo et al. 2010), it is 
hypothesised  that  this  mechanism  might  partly  be  responsible  for  the  here  described 
neuroprotective  effect  of  GPR55  activation  by  LPI.  Ca
2 +  influx  was  regulated  by  LPI  in 99 
 
cerebellar  granule  neurons  through  store  operated  Ca
2 +  entry  channels  at  the  plasma 
membrane  (Smani,  Dominguez-Rodriguez  et  al.  2007).  LPI-induced  Ca
2 +  influx  can  be 
mediated through channels belonging to the transient receptor potential (TRP) family (Vanden 
Abeele, Zholos et al. 2006; Andersson, Nash et al. 2007; Monet, Gkika et al. 2009). The used 
amount of LPI in the present study as well as the cells used, seem to influence the Ca
2 + 
mediated signal. Known from literature, LPI can exert various effects also on other membrane 
channels (Maingret, Patel et al. 2000; Patel, Lazdunski et al. 2001). In particular, TREK and 
TRAAK K
+ channels become activated by LPI, which have an important regulatory role on 
the control of the membrane potential of neurons (Patel, Lazdunski et al. 2001).  
However, further evidence is needed to clarify the downstream signaling of GPR55 and its 
neuroprotective mechanism but also whether it should become a cannabinoid receptor. 
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Conclusion 
Taken together, the activation of the eCBS after neuronal damage by transection of long-
range projections apparently provides a strong time-dependent and area confined signal for de 
novo synthesis of eCB, presumably to prevent or restrict neuronal damage. The present data 
underlines the importance of eCB in CNS pathologies and helped to identify a site-specific 
intrinsic regulation of eCB levels in long-range projection damage. The highly dynamic eCBS 
represents  an  endogenous  protective  system  and  might  be  involved  in  dendritic  re-
organisation in the CNS. The present results should be followed up by in vivo experiments to 
sustain  the  temporal  regulation  and  determine  optimal  treatment  possibilities.  Other  long 
range projections e.g. denervated neurons in the spinal cord should be considered as a source 
for eCB and their regulation after transection of long range somato-afferent projections and 
long range somato-efferent projections needs to be investigated. 
Recently, GPR55 is discussed as potential CB3. In the present study it could be shown that 
GPR55 mediated neuroprotection after excitotoxic lesion in OHSC.  After microglia depletion 
the GPR55 ligand  LPI  lost its  neuropotective  property, suggesting a microglia dependent 
mechanism. Still, further research is needed to understand the role of GPR55 in neuronal 
protection and the present experiments should be sustained by in vivo studies.  
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